DE2262413A1 - Direkte radioimmunpruefung auf antigene und ihre antikoerper - Google Patents
Direkte radioimmunpruefung auf antigene und ihre antikoerperInfo
- Publication number
- DE2262413A1 DE2262413A1 DE2262413A DE2262413A DE2262413A1 DE 2262413 A1 DE2262413 A1 DE 2262413A1 DE 2262413 A DE2262413 A DE 2262413A DE 2262413 A DE2262413 A DE 2262413A DE 2262413 A1 DE2262413 A1 DE 2262413A1
- Authority
- DE
- Germany
- Prior art keywords
- antigen
- coating
- antibody
- solution
- buffer mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Die Erfindung betrifft ein diagnostisches Verfahren zur
Durchführung einer Radioimmunprüfung auf Antigene und ihre Antikörper, sowie ein Verfahren zur Herstellung eines Überzuges bei einer für diese Prüfung verwendbaren Vorrichtung. Insbesondere batrifft die Erfindung ein direktes Verfahren zur Bestimmung von Hepatitis vergesellschafteten Antigenen und ihren Antikörpern sowie ein Verfahren zur Herstellung einer hierfür verwendbaren diagnostischen Vorrichtung.
Durchführung einer Radioimmunprüfung auf Antigene und ihre Antikörper, sowie ein Verfahren zur Herstellung eines Überzuges bei einer für diese Prüfung verwendbaren Vorrichtung. Insbesondere batrifft die Erfindung ein direktes Verfahren zur Bestimmung von Hepatitis vergesellschafteten Antigenen und ihren Antikörpern sowie ein Verfahren zur Herstellung einer hierfür verwendbaren diagnostischen Vorrichtung.
Es sind zwar schon eine Anzahl Verfahren zur Peststellung
der Anwesenheit von antigen-aktiven Makromolekülen, wie
intakten Viren, Viruskapsiden (virus capsids), Virusuntereinheiten, Bakterien, Membranen, Zellwänden, Hormonen usw.,
intakten Viren, Viruskapsiden (virus capsids), Virusuntereinheiten, Bakterien, Membranen, Zellwänden, Hormonen usw.,
309827/1134
bekannt, jedoch fehlte es bisher an einer einfachen und doch empfindlichen Prüfmethode und -vorrichtung zur Feststellung
der Anwesenheit dieser Materialien. Virushepatitis, einschließlich
der sogenannten Serumhepatitis, die eine verhältnismäßig
häufig auftretende Krankheit ist, konnte bisher nicht leicht durch einen Test, der sowohl spezifisch als auch reproduzierbar
ist und eine rasche Feststellung, ob das Serum eines Patienten oder eines Spenders Hepatitis vergesellschaftete
Antigene oder Antikörper enthält oder nicht, diagnostiziert werden.
Für verschiedene Antigen/Antikörper-Materialien sind schon
Radioimmunprüfmethoden entwickelt worden. Diese Prüfmethoden,
wie sie beispielsweise von Kevin Catt et al in "journal of Biochemistry", I966, Band 100, S. 31c und 33c und in "Science",
Band I58, S, 1570, 1967, beschrieben sind, sind indirekte Prüfungen,
bei denen die anwesende Menge an Antigen der von dem Tracer emittierten Strahlung etwa umgekehrt proportional ist.
Diese Prüfmethoden erforderten die Verwendung von Korrelationstabellen und anderen Materialien, so daß die Ergebnisse schlecht
reproduzierbar und ungenau waren.
Durch die vorliegende Erfindung v/erden diese Schwierigkeiten, d.h. der Mangel an Reproduzierbarkeit und Genauigkeit einer
solchen Untersuchung, überwunden. Das Verfahren gemäß der Erfindung besteht darin, daß man eine Probe eines unbekannten
Serums mit einer Vorrichtung, die mit einem Antikörper-Überzug versehen ist, in Kontakt bringt, die Prüfvorrichtung
und das Serum 1/2 bis h2 Stunden bebrütet, absaugt und wäscht,
einen J-125 als Tracer enthaltenden Antikörper mit dem Serum und der mit dem Überzug versehenen Vorrichtung in Kontakt bringt
und 1 bis 6 Stunden bebrütet, absaugt und wäscht und die J-125-Gamma-Strahlung
der Vorrichtung auszählt.
Hauptaufgabe der Erfindung ist also ein neues Verfahren zur direkten
Bestimmung von Antigenen und ihren Antikörpern.
309827/11 3A
Eine weitere Aufgabe der Erfindung ist ein Verfahren zur Herstellung
eines Überzuges auf einer diagnostischen Vorrichtung für eine Verwendung bei Radioimmunbestimmungen.
Eine weitere Aufgabe der Erfindung ist ein Verfahren zur
raschen und genauen Bestimmung der Anwesenheit von Hepatitis vergesellschafteten Antigenen oder Antikörpern im Serum.
Die Zeichnung zeigt eine mit einem Überzug versehene Prüfvorrichtung
für die Durchführung des Verfahrens gemäß der Erfindung im Schnitt.
Die Vorrichtung 1 hat die Form eines Teströhrchens mit .einem
mit einem Überzug versehenen Teil 2. Dieser Teil 2 besitzt einen Überzug aus einem Antigen oder seinem Antikörper, vorzugsweise,
wie gezeigt, im Bodenteil des Röhrchens. Das Verfahren gemäß der Erfindung kann aber auch mit anders als in
der Zeichnung gezeigt ausgebildeten Vorrichtungen durchgeführt ■
werden.
Wie erwähnt, weist der Teil 2 der Vorrichtung 1 einen Überzug aus entweder einem Antigen oder einem Antikörper auf, je nachdem,
was für ein Material untersucht werden soll. Das Verfahren gemäß der Erfindung ist auf fast alle Antigene und Antikörper in gleicher
Weise anwendbar, und die Herstellung des Überzuges soll im folgenden unter Bezugnahme auf einen bestimmten Hepatitis vergesellschafteten
Antikörper, d.h. Anti-Australien-Antigen (anti-Australia
antigen) , beschrieben werden. Eine Anti-Australien-Antigen
-Lösung mit einer Konzentration von etwa 1 bis etwa
100 μg Eiweiß/ml wird aus einem Anti-Australien-Antigen-Serum
in etwa 0,005 bis etwa 0,02m 2-Amino-2-hydröxymethyl-:l. ,^-propandiol-HCl
(Tris-HCl) hergestellt. Das Tris-HCl die.nt als Puffer zur Einstellung des' pH der Lösung auf etwa 7,1 bis etwa 9,5 zusammen
mit etwa 0,01$ bis etwa 0,0'j/j Natriumazid. Mit dieser
Anti-Australien-Antigen-Lösung wird dann der Überzug auf die
Oberfläche des Röhrchens aufgebracht und 6 bis 72 Stunden, vor-
309827/1134
zugsweise 12 bis 48 Stunden, bei Raumtemperatur bebrütet. Die mit dem überzug versehenen Röhrchen werden dann mit etwa 0,(005
bis etwa 0,02m Tris-HCl vom pH 6,9 bis 8,4 plus etwa 0,01% bis
etwa 0,05/6 Natriumazid gewaschen. Nach diesem Waschen und Spülen
können die TestrÖhrchen bei 40C aufbewahrt werden, bis sie
für eine Radiοimmunprüfung gebraucht werden.
Vorzugsweise wird sowohl für das Inkubationsmedium als auch
die Waschflüssigkeit eine auf pH 7,1 eingestellte 0;01m Lösung
von Tris-HCl und 0,02$ Natriumazid verwendet.
Die Menge an Antikörper oder Antigen, die in dem überzug des
Röhrchens anwesend ist, ist nicht kritisch, weil der Test jedesmal
im Vergleich mit wenigstens einem Leertest durchgeführt wird. Für die Auswertung des Tests gemäß der Erfindung sind
keine genormten Kurven oder Auftragungen erforderlich. D.h. in dem Überzug muß keine bestimmte Menge an Antikörper oder Antigen
anwesend sein, sofern zwei gleiche Röhrchen verwendet werden.
Der überzug muß natürlich nicht auf ein TestrÖhrchen, sondern kann auch beispielsweise auf einen Einsatz für einen Schacht
usw. aufgebracht werden, indem man den Einsatz in die Antigen- oder Antikörper-Lösung eintaucht und im übrigen nach dem oben
beschriebenen Verfahren verfährt.
Antigene und Antikörper, die nach dem Verfahren gemäß der Erfindung
bestimmt werden können, sind beispielsweise: verschiedene intakte Viren, Viruskapsiden, Virusuntereinheiten, Bakterien,
Membranen, ZeJlwände, verschiedene Hormone, Gammaglobuline
usw. Wesentlich ist nur, daß diese Materialien mindestens
zwei antigen-aktive Stellen besitzen. Außerdem sind
Antigene und Antikörper mit mehreren kombinierenden Stellen auch in Anwesenheit der entsprechenden Antikörper und Antigene
auffindbar, sofern wenigstens zwei freie kombinierende Stellen verfügbar bleiben. Der Radioirnmuntest gemäß der Er-
309827/1134
findung eignet sich zwar zur Auffindung aller obigen Materialien, insbesondere aber zur Peststellung der Anwesenheit von Hepatitis
vergesellschafteten Antigenen und Antikörpern, wie Australien-Antigen
und Anti-Australien-Antigen, und dieser Test stellt daher
die bevorzugte Durchführungsform des Verfahrens gemäß der Erfindung dar.
Das Verfahren gemäß der Erfindung wird im folgenden für bestimmte Materialien und die zur Durchführung des direkten
Radioimmuntests zur Peststellung der Anwesenheit von Hepatitis
vergesellschafteten Australien-Antigen beschrieben»
Zunächst wird eine abgemessene Probe Plasma oder Blut, die auf Hepatitis vergesellschaftetes Antigen untersucht werden soll,
in ein Teströhrehen mit einem Anti-Australien-Antigeη-Überzug
eingebracht» Das Material wird 1/2 bis 52 Stunden, vorzugsweise
12 bis 24 Stunden, bei Raumtemperatur bebrütet und dann mit
dem Puffergemisch, d.h. Tris-HCl und Natriumazid, gewaschen.
Dann wird dem Röhrchen oder dem Aufnahmeschacht eine abgemessene
Menge Anti-Australien-Antigen mit gereinigtem J-I25
als Tracer zugesetzt, und das damit in Kontakt stehende Röhrchen oder der Einsatz wird für weitere 1 bis 24 Spunden, vorzugsweise
1 1/2 bis 6 Stunden, bei Raumtemperatur bebrütet. Danach wird der Inhalt mit dem Puffergemisch gewaschen, und
das Röhrchen wird in einen Zähler, der Gamma-Strahlung nachzuweisen
vermag, eingesetzt. Gleichzeitig werden in gleicher Weise Vergleichstests unter Verwendung eines normalen Plasma statt
des zu untersuchenden durchgeführt. Wenn das unbekannte Plasma■.
einen höheren Gamma-Strahlungswert ergibt als die Vergleichsprobe, wird es als hepatitis-antigen-positiv angesehen.
Im allgemeinen erfolgt die Auszählung; vorzugsweise für 1 Minute.
Wenn jedoch eine Probe der oberen Grenze der Vergleiohsprobe
sehr nahe kommt, kann eine längere Auszählung bis zu 10 Minuten angewandt werden, damit genaue Ergebnisse erhalten werden»
309827/1134
Wie oben erwähnt, erfolgt die Bebrütung Im allgemeinen bei Raumtemperatur.
Um die Bebrütungszeit abzukürzen, kann jedoch leicht,
d.h. bis zu etwa 550C* erwärmt werden.
Das Puffermedium enthält im allgemeinen etwa 0,005 bis etwa 0,02m Tris-HCl und etwa 0,01 bis 0,05 Gew.-^ Natriumazid bei einem pH
von 6,9 bis 8,4. Der bevorzugte Puffer enthält 0,01m Tris-HCl und 0,02 Gew.-% Natriumazid.
Im allgemeinen wird der Test mit unverdünntem Blutserum oder Plasma durchgeführt. Wenn jedoch nur begrenzt Proben zur Verfügung
stehen, kann die Probe in geeigneter Verdünnung mit normalem Serum oder Plasma, wie RInderserumalbumen oder einem
Puffergemisch, wie einem Gemisch von Tris-HCl und Natriumazid, einem Gemisch von Tris-HCl, Natriumazid und X% Hinderserumalbumen
usw., verwendet werden.
Auch kann statt des bevorzugten radioaktiven Materials J-125
auch jedes andere allgemein als Tracer für Antigene oder Antikörper in Radioimmuntests verwendete radioaktive Isotop verwendet
werden.
Wie erwähnt, ist das Verfahren gemäß der Erfindung ein direkter Radioimmuntest zur Feststellung verschiedener Antigene und ihrer
Antikörper, insbesondere des Hepatitis vergesellschafteten Antigens oder seines Antikörpers. Wenn das Hepatitis vergesellschaftete
Antigen quantitativ bestimmt werden soll, kann eine genormte Kurve, die direkt die Beziehung zwischen den Auszählungen
je Minute und der Menge an Hepatitis vergesellschaftetem Antigen wiedergibt, verwendet werden.
Das folgende Beispiel veranschaulicht die Erfindung. Angaben in Teilen und Prozent beziehen sich auf das Gewicht.
309827/1134
Das in der Zeichnung gezeigte Röhrchen, das aus Polystyrol besteht,
wird mit einem gereinigten Hepatitis vergesellschafteten Antikörper überzogen. Dieser Überzug wird aufgebracht, indem man
die Oberfläche des Röhrchens einer verdünnten Lösung von Hepa- .-titis
vergesellschaftetem Antikörper in 0,01m Tris-HPl vom pH
7,1 und 0,02 Gew.-% Natriumazid aussetzt, und das'mit dem Überzug versehene Röhrchen «wird dann 1 Tag bei Raumtemperatur bebrütet.
Dann wird das Röhrchen mit (aliquots of) 0,Ölm Tris-HCl plus 0,02 Gew.-% Natriumazid gewaschen. Diese Röhrchen können
bis zu ihrer .Verwendung bei 40C aufbewahrt werden. In jedes von
drei mit Hepatitis vergesellschaftetem Antikörper überzogenen Röhrchen wird eine Plasmaprobe von lOOu 1. eingebracht. Eine
dieser Plasmaproben ist die unbekannte, die anderen beiden sind negativ hinsichtlich Hepatitis vergesellschaftetem Antigen.
Jede Stufe des Verfahrens wird auf jede der drei Proben angewandt. Die beiden negativen Proben ergeben die Strahlungswerte,
mit denen der Strahlungswert der unbekannten Probe schließlich verglichen wird. Die Proben werden beiseite gestellt und
18 Stunden bei Raumtemperatur bebrütet. Danach werden sie mit gleichen Teilen (aliquots) des Inkubationspuffergemisches gewaschen.
Zu diesem Zeitpunkt werden 2,5 ng Hepatitis vergesellschaftetem gereinigtem Antikörper mit J-125 als Tracer in 0,1 ml
Volumen in jedes Röhrchen eingebracht. Die Röhrchen werden erneut
beiseite gestellt und 2 Stunden .bebrütet, wonach die Röhrchen
erneut mit gleichen Teilen (aliquots) an dem Inkubationspuffergemisch gewaschen werden. Jede der negativen Plasmaproben
wird mit einem herkömmlichen Strahlungszähler mit einem Einsatzüchacht,
der Gamma-Strahlung aufzuzeigen vermag, ausgezählt. Die negativen Proben werden 1 Minute ausgezählt, und der Mittelwert
der Zählrate je Minute wird bestimmt; in diesem Fall 200 Zählungen je Minute. Dann wird die unbekannte Probe in der gleichen
Weise ausgezählt, und die Zählrate wird mit dem Mittelwert je Minute der negativen Plasmaproben plus einem Korrekturfaktor
gleich 50% dor Zählrate je Minute der negativen Probe verglichen.
Die unbekannte Plasmaprobe hat in diesem Pail eine Zähl-
309827/1134
— ι —
rate von 400 Auszählungen je Minute, die höher ist als die
Zählrate 300, d.h. 200 plus $0% von 200 = 300, die das Maximum
für einen negativen Test darstellt.
Das oben beschriebene Verfahren stellt einen einfachen Ja/ Nein-Test auf die Anwesenheit oder Abwesenheit von Hepatitis
vergesellschaftetem Antigen in einer unbekannten Probe von Blut oder Plasma dar. Obwohl ein Korrekturfaktor erforderlich
ist, läßt der Test Schlüsse zu und ist reproduzierbar und von großer Genauigkeit.
309827/1134
Claims (1)
- 22S2413P ate η t a η s ρ r ji.e.h e[T) Verfahren zu? Feststellung der Anwesenheit von Äntigenen und ihren Antikörpern in einer unbekannten Probe, durch eine direkte Radioimmunprüfung, dadurch ge kennzeichnet , daß man(a) die Probe mit einem Überzug aus einem Antigen oder seinem Antikörper in Kontakt bringt;(b) die Probe ein erstes Mal bebrütet, während sie wiit diesem Überzug in Kontakt steht!(c) den bebrüteten. Überzug wäscht;(d) den gewaschenen Überzug mit einem einen radioaktiven Tracer enthaltenden gereinigten Antigen oder seinem Antikörper in Kontakt bringt mit der Maßgabe,, daß das den Tracer enthaltende Material das Antigen ist, wenn der Überzug das Antigen ist, und der Antikörper, wenn der Überzug der Antikörper ist\(e) den gewaschenen Überzug ein zweites Mal bebrütet, während er mit dem den !Radioaktiven Tracer enthaltenden Material in Kontakt steht;(f) den bebrüteten Überzug wäscht;(g) die von dem Überzug emittierte Strahlung auszählt und(h) die von diesem Überzug erhaltene Zählrate mit der Zählrate einer negativen, gemäß den obigen Stufen (a) bis (g) hergestellten Probe vergleicht«309827/11342. Verfahren nach Anspruch 1, dadurch gekennzeichnet , daß das Antigen oder sein Antikörper
ein Hepatitis vergesellschaftetes Antigen oder sein Antikörper ist.J5. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß das Hepatitis vergesellschaftete
Antigen oder sein Antikörper als radioaktiven Tracer J-125 enthält.4. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die erste Bebrütung für 1/2 bis 42 Stunden durchgeführt wird.5. Verfahren nach Anspruch ~5, dadurch gekennzeichnet, daß die erste Bebrütung für 1/2 bis 42 Stunden durchgeführt wird.6. Verfahren nach Anspruch 1, dadurch gekennzeichnet , daß das pH der unbekannten Probe mit
einem Puffergemisch aus 0,02 Gew.-^ Natriumazid und 1 Gew.-% Rinderserumalbumen in einer 0,01m Lösung von 2-Amino-2-hydroxymethyl-ljJ-propandioL-hydrochlorid auf 6,9 bis 8,4 eingestellt wird.7. Verfahren nach Anspruch 3* dadurch gekennze lehnet , daß das pH der unbekannten Probe mit
einem Puffergemisch aus 0,02 Gew.-% Natriumazid und 1 Gew.-% Rinderserumalbumen in einer 0,01m Lösung von 2-Amino-hydroxymethyl-l,j5-propandiol-hydrochlorid auf 6,9 bis 8,4 eingestellt wird.8. Verfahren nach Anspruch J, dadurch gekennzeichnet, daß die erste Bebrütung für 1/2 bis 42 Stunden erfolgt.309827/1134- 10 -■ · ■ 41 22&24139. Verfahren nach Anspruch 1, dadurch gekennz e lehnet , daß der Überzug.beide Male mit einem Puffergemisch aus 0,02 Gew.-% Natriumazid in einer 0,01m · Lösung von 2-Amino-hydroxymethyl-l,3-propandioi-hydrochloriä gewaschen wird.10. Verfahren nach Anspruch 8, dadurch g e'k e η η zeichnet, daß der Überzug beide Male mit einem Puffergemisch aus 0,02 Gew.-% Natriumazid in einer 0,01m Lösung von 2-Amino-hydroxymethyl-l,3-propandiol-hydrochlorid gewaschen wird.11. Verfahren nach Anspruch 1, dadurch gekennzeichnet-, daß die zweite. Bebrütung für 1 bis 24 Stunden bei Raumtemperatur durchgeführt wird.12. Verfahren nach Anspruch 10, dadurch gekennzeichnet , daß die zweite Bebrütung für 1 bis 24 Stunden bei Raumtemperatur durchgeführt wird.15. Verfahren zur Herstellung eines Überzuges auf einer Testvorrichtung für die direkte Radioimmunprufung auf Antigene oder deren Antikörper, dadurch gekennzeichnet, daß maneine Lösung eines Antigens oder seines Antikörpers in einem Puffergemisch herstellt;die Testvorrichtung mit dieser Lösung in Kontakt bringt;die Testvorrichtung 6 bis 72 Stunden bebrütet unddie bebrütete Testvorrichtung mit dem Puffergemisch wäscht.lh. Verfahren nach Anspruch \J>3 dadurch gekennze ic'hnet , daß das Antigen oder sein Antikörper309827/1134- 11 -Hepatitis vergesellschaftetes Antigen oder sein Antikörper ist.15. Verfahren nach Anspruch 13» dadurch gekennzeichnet y daß das Puffergemisch 0,02 Gew.-# Natriumazid in einer 0,01m Lösung von 2-Amino-hydrcocymethyl-l,3-propandiol-hydrochlorid enthält.16. Verfahren nach Anspruch 14, dadurch gekennzeichnet , daß das Puffergemisch 0,02 Gew.-% Natriumazid in einer 0,01m Lösung von 2-Amino-hydroxymethyl-l,3-propandiol-hydrochlorid enthält.17. Verfahren nach Anspruch 16, dadurch gekennzeichnet , daß die Testvorrichtung in die Lösung getaucht wird.18. Verfahren nach Anspruch 17, dadurch gekennzeichnet, daß die Testvorrichtung in die Lösung|:j I.getaucht wird.309827/1134- 12 -
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US210510A US3867517A (en) | 1971-12-21 | 1971-12-21 | Direct radioimmunoassay for antigens and their antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2262413A1 true DE2262413A1 (de) | 1973-07-05 |
DE2262413B2 DE2262413B2 (de) | 1977-11-17 |
Family
ID=22783190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19722262413 Ceased DE2262413B2 (de) | 1971-12-21 | 1972-12-20 | Verfahren zur feststellung der anwesenheit eines zur bindung an zwei hepatitis-antikoerper bzw. -antigene befaehigten hepatitis-antigens bzw. -antikoerpers in einer unbekannten probe durch radioimmunpruefung |
Country Status (13)
Country | Link |
---|---|
US (1) | US3867517A (de) |
AT (1) | AT326818B (de) |
AU (1) | AU470050B2 (de) |
BE (1) | BE793061A (de) |
CA (1) | CA988420A (de) |
CH (2) | CH568061A5 (de) |
DE (1) | DE2262413B2 (de) |
FR (1) | FR2164705B1 (de) |
GB (1) | GB1414480A (de) |
IT (1) | IT988084B (de) |
NL (1) | NL7217371A (de) |
PH (1) | PH13655A (de) |
ZA (1) | ZA728798B (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0019504A1 (de) * | 1979-04-20 | 1980-11-26 | Merck & Co. Inc. | RIA für Hepatitis-A-Antigen und Antigen-Antikörper-Radionuclid dafür |
Families Citing this family (855)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4012494A (en) * | 1971-12-21 | 1977-03-15 | Abbott Laboratories | Direct radioimmunoassay for antigens and their antibodies |
US3949064A (en) * | 1973-10-26 | 1976-04-06 | Baxter Laboratories, Inc. | Method of detecting antigens or antibodies |
US4172117A (en) * | 1974-05-20 | 1979-10-23 | Biotest-Serum-Institut Gmbh | Method for the simultaneous measurement of antigens and their antibodies by solid-phase radioimmunoassay |
US3959650A (en) * | 1974-08-26 | 1976-05-25 | Intelcom Rad Tech | Method for detecting and identifying allergy |
DK140815B (da) * | 1975-06-10 | 1979-11-19 | Weeke Bengt | Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden. |
US4034072A (en) * | 1975-07-21 | 1977-07-05 | Corning Glass Works | Serum hepatitis test |
USRE32696E (en) * | 1975-09-04 | 1988-06-14 | Akzona Incorporated | Enzymatic immunological method for determination of antigens and antibodies |
US4474878A (en) * | 1975-09-29 | 1984-10-02 | Cordis Laboratories, Inc. | Sandwich EIA for antigen associated with hepatitis |
SE7610683L (sv) * | 1975-09-29 | 1977-06-10 | Cordis Corp | Metod for bestemning av nervaron av ett antigen associerat med hepatit |
US4642285A (en) * | 1975-09-29 | 1987-02-10 | Diamedix Corporation | Sandwich EIA for antigen |
GB1533272A (en) * | 1976-02-13 | 1978-11-22 | Radiochemical Centre Ltd | Centrifuge tube |
JPS5851000B2 (ja) * | 1976-04-16 | 1983-11-14 | アボツト ラボラトリ−ズ | スルホリトコリルグリシルチラミンの製造法 |
US4272510A (en) * | 1976-04-26 | 1981-06-09 | Smith Kendall O | Magnetic attraction transfer process for use in solid phase radioimmunoassays and in other assay methods |
US4120945A (en) * | 1976-07-06 | 1978-10-17 | Becton, Dickinson & Company | Substrate coated with receptor and labeled ligand for assays |
US4210418A (en) * | 1976-08-30 | 1980-07-01 | Mallinckrodt, Inc. | Container for immunochemical and enzymatical determinations or procedures |
GB1572220A (en) * | 1976-10-07 | 1980-07-30 | Mochida Pharm Co Ltd | Immunochemical process of measuring physiologically active substances |
US4090850A (en) * | 1976-11-01 | 1978-05-23 | E. R. Squibb & Sons, Inc. | Apparatus for use in radioimmunoassays |
CA1100037A (en) * | 1977-03-11 | 1981-04-28 | Chung-Mei Ling | Hb.sub.c ag coated on solid phase |
US4200613A (en) * | 1977-06-03 | 1980-04-29 | Ramco Laboratories Inc. | Radioimmunoassay apparatus |
US4197287A (en) * | 1977-06-10 | 1980-04-08 | Ventrex Laboratories Inc. | Method and apparatus for performing in nitro clinical diagnostic tests using a solid phase assay system having special utility for use with automatic pipetting equipment |
US4225575A (en) * | 1978-05-15 | 1980-09-30 | Ventrex Laboratories, Inc. | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system |
US4320087A (en) * | 1978-01-23 | 1982-03-16 | Abbott Laboratories | Laboratory assay device |
US4256629A (en) * | 1978-02-06 | 1981-03-17 | Research Corporation | Antigen for early pregnancy test and contraceptive vaccine |
US4451434A (en) * | 1978-03-27 | 1984-05-29 | Hiram Hart | Transparent optical container for non-destructive biological fluid assay |
US4189464A (en) * | 1978-05-05 | 1980-02-19 | Institute For Cancer Research | Hepatitis B testing reagent and method |
US4292403A (en) * | 1978-08-24 | 1981-09-29 | Akzona Incorporated | Detection and/or determination of IgM, IgA, IgD and IgE immunoglobulins |
US4356164A (en) * | 1979-05-21 | 1982-10-26 | Govt. of the U.S., as represented by the Secretary, Dept. of Health & Human Services | Detection of non-A, non-B hepatitis associated antigen |
US4289748A (en) * | 1979-05-31 | 1981-09-15 | United States Of America | Ultrasensitive enzymatic radioimmunoassay method |
CA1148859A (en) * | 1979-06-14 | 1983-06-28 | Lacy R. Overby | Simultaneous assay of two hepatitis viruses using a solid phase |
US4378344A (en) * | 1979-09-28 | 1983-03-29 | Ventrex Laboratories, Inc. | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system |
EP0146654A3 (de) * | 1980-06-20 | 1986-08-20 | Unilever Plc | Verfahren und Vorrichtung zur Durchführung von spezifischen Bindungstesten |
US6406920B1 (en) | 1980-06-20 | 2002-06-18 | Inverness Medical Switzerland Gmbh | Processes and apparatus for carrying out specific binding assays |
US4363634A (en) * | 1980-07-18 | 1982-12-14 | Akzona Incorporated | Glass support coated with synthetic polymer for bioprocess |
US4357142A (en) * | 1980-07-18 | 1982-11-02 | Akzona Incorporated | Glass support coated with synthetic polymer for bioprocess |
US4486530A (en) * | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
WO1982001773A1 (en) * | 1980-11-07 | 1982-05-27 | Secher David S | Assay for interferon |
US4474892A (en) * | 1983-02-16 | 1984-10-02 | Board Of Trustees Of The Leland Stanford Junior University | Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same |
US4563184A (en) * | 1983-10-17 | 1986-01-07 | Bernard Korol | Synthetic resin wound dressing and method of treatment using same |
US4861588A (en) * | 1985-02-05 | 1989-08-29 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US4847080A (en) * | 1984-03-07 | 1989-07-11 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers |
US5204096A (en) * | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US5158769A (en) * | 1984-03-07 | 1992-10-27 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US4804626A (en) * | 1986-10-22 | 1989-02-14 | The General Hospital Corporation | Immunometric assay for the detection of human chorionic gonadotropin |
US5061619A (en) * | 1987-11-05 | 1991-10-29 | Connaught Laboratories Limited | Immunoassay using antibody-antigen conjugates |
US5614504A (en) * | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
US6168956B1 (en) | 1991-05-29 | 2001-01-02 | Beckman Coulter, Inc. | Multiple component chromatographic assay device |
US5998220A (en) * | 1991-05-29 | 1999-12-07 | Beckman Coulter, Inc. | Opposable-element assay devices, kits, and methods employing them |
US5877028A (en) * | 1991-05-29 | 1999-03-02 | Smithkline Diagnostics, Inc. | Immunochromatographic assay device |
US5874423A (en) * | 1992-09-10 | 1999-02-23 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Digitalis-like compounds |
AU679008B2 (en) * | 1993-05-06 | 1997-06-19 | Chiron Diagnostics Corporation | Mixed luminescent conjugate test assays |
AU2635295A (en) * | 1994-06-13 | 1996-01-05 | Henry Ford Health System | A novel neuronal-neonatal gene: neuronatin |
US5843673A (en) * | 1994-10-25 | 1998-12-01 | Curators Of The University Of Missouri | Method of screening for endometriosis |
US6531277B2 (en) | 1994-10-25 | 2003-03-11 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
US6416714B1 (en) * | 1995-04-25 | 2002-07-09 | Discovery Partners International, Inc. | Remotely programmable matrices with memories |
US5741462A (en) * | 1995-04-25 | 1998-04-21 | Irori | Remotely programmable matrices with memories |
US5874214A (en) * | 1995-04-25 | 1999-02-23 | Irori | Remotely programmable matrices with memories |
US6329139B1 (en) | 1995-04-25 | 2001-12-11 | Discovery Partners International | Automated sorting system for matrices with memory |
US6331273B1 (en) | 1995-04-25 | 2001-12-18 | Discovery Partners International | Remotely programmable matrices with memories |
US5751629A (en) * | 1995-04-25 | 1998-05-12 | Irori | Remotely programmable matrices with memories |
US6017496A (en) * | 1995-06-07 | 2000-01-25 | Irori | Matrices with memories and uses thereof |
US5728807A (en) * | 1995-05-16 | 1998-03-17 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Mutated proteins associated with ataxia-telangiectasia |
US5777093A (en) * | 1995-05-16 | 1998-07-07 | Ramot-University Authority For Applied Research & Industrial Development Ltd. | cDNAs associated with ataxia-telangiectasia |
US5858661A (en) * | 1995-05-16 | 1999-01-12 | Ramot-University Authority For Applied Research And Industrial Development | Ataxia-telangiectasia gene and its genomic organization |
JP2002515965A (ja) * | 1995-08-18 | 2002-05-28 | ダブリュー. ランドリ,ドナルド | 抗体触媒反応の調節による有機化合物の検出 |
US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
DE19730497C2 (de) * | 1997-07-16 | 2000-02-10 | Heermann Klaus Hinrich | Verfahren zum Waschen, zur Separierung und Konzentrierung von Biomolekülen unter Verwendung eines Magnetstifts |
US7973156B2 (en) * | 1997-08-21 | 2011-07-05 | Quark Pharmaceuticals Inc. | Hypoxia-regulated genes |
US20030104973A1 (en) * | 1997-08-21 | 2003-06-05 | Quark Biotech, Inc. | Hypoxia-regulated genes |
DE69829857T2 (de) | 1997-08-21 | 2006-02-02 | Quark Biotech, Inc., Pleasanton | Hypoxie-regulierte gene |
US6284496B1 (en) | 1997-10-03 | 2001-09-04 | University Of South Florida | DNA vector for determining the presence of out-of-reading-frame mutations |
CA2307345A1 (en) | 1997-10-17 | 1999-04-29 | University Of South Florida | Method to diagnose and monitor cellular immune deficiencies |
US7687057B2 (en) | 1998-01-09 | 2010-03-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs, and uses related thereto |
US20080206206A1 (en) | 1998-05-07 | 2008-08-28 | University Of South Florida | Bone marrow-derived neuronal cells |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
US7605149B1 (en) | 1998-07-13 | 2009-10-20 | University Of South Florida | Modulation of the phospholipase A2 pathway as a therapeutic |
US6187563B1 (en) | 1998-08-07 | 2001-02-13 | Yale University | βIV-spectrin-polypeptides and nucleic acids encoding same |
BR9914465A (pt) * | 1998-09-29 | 2001-10-09 | Gamida Cell Ltd | Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células |
MXPA01007820A (es) * | 1999-02-04 | 2003-06-19 | Technion Res & Dev Foundation | Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras. |
US6440682B1 (en) * | 1999-05-28 | 2002-08-27 | Detroit R&D Inc. | Detection of hypertension using immunoreactive metabolic products |
US6787318B1 (en) * | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
US20060127366A1 (en) * | 1999-06-25 | 2006-06-15 | Mitrani Eduardo N | Method and device for inducing biological processes by micro-organs |
AU5423300A (en) * | 1999-06-25 | 2001-01-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of inducing angiogenesis by micro-organs |
US6875582B1 (en) | 1999-08-19 | 2005-04-05 | Omniscience Pharmaceuticals, Inc. | Methods and targets of antibiotic resistance |
US7811981B2 (en) * | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
US7101839B1 (en) | 1999-08-30 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
AU784258B2 (en) | 1999-11-19 | 2006-03-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Aspegillus niger beta-glucosidase gene, protein and uses thereof |
US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
AU2001225441A1 (en) * | 2000-01-24 | 2001-07-31 | Agricultural Research Organization The Volcani Center | Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby |
ATE472601T1 (de) | 2000-03-27 | 2010-07-15 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
IL135884A (en) * | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
HUP0300810A2 (hu) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
PT2078531E (pt) | 2000-08-08 | 2012-08-06 | Technion Res & Dev Foundation | Composições farmacêuticas e métodos úteis para modular a angiogénese |
EP1683874A3 (de) | 2000-08-29 | 2006-10-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Verfahren zur Isolierung von Genen, die für Proteine mit spezifischer Funktion kodieren, und zur Auslese von pharmazeutisch aktiven Wirkstoffen |
US7632522B2 (en) * | 2000-09-28 | 2009-12-15 | Nanocyte Inc. | Use of stinging cells/capsules for the delivery of active agents to keratinous substances |
US20070281037A9 (en) * | 2000-09-28 | 2007-12-06 | Nanocyte Inc. | Sterile preparations and compositions including stinging capsules and methods of producing and using same |
WO2002026191A2 (en) * | 2000-09-28 | 2002-04-04 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
ES2425321T3 (es) | 2000-11-17 | 2013-10-14 | Vascular Biogenics Ltd. | Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos |
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2002218461B2 (en) | 2000-11-24 | 2006-09-07 | Vascular Biogenics Ltd | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
EP2357478A3 (de) | 2000-11-30 | 2011-11-16 | Crawford Healthcare Holdings Limited | Krankheitsdiagnose |
WO2002043651A2 (en) * | 2000-11-30 | 2002-06-06 | Yeda Research And Development Co. Ltd. | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
US20050202098A1 (en) | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
US20050031618A1 (en) * | 2001-01-31 | 2005-02-10 | Dror Mevorach | Induction of tolerance by apoptotic and/or necrotic cells |
US20020117169A1 (en) | 2001-02-27 | 2002-08-29 | Kurz Daniel R. | Cover and applicator for a portion of a mammalian body |
US20030003454A1 (en) | 2001-03-23 | 2003-01-02 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer |
US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
IL159944A0 (en) * | 2001-07-19 | 2004-06-20 | Yissum Res Dev Co | Polypeptides having carotenoid isomerase catalytic activity, nucleic acids encoding same and uses thereof |
US7442781B2 (en) | 2001-08-16 | 2008-10-28 | Urifer Ltd. | Diagnosis, prevention and treatment of cancer |
US7138144B2 (en) * | 2001-09-07 | 2006-11-21 | Nadir Askenasy | Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation |
US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
MXPA04003514A (es) | 2001-10-19 | 2004-07-23 | Vascular Biogenics Ltd | Construcciones de polinucleotidos, composiciones farmaceuticas y metodos para reducir la regulacion dirigida de angionesis y terapia anticancer. |
WO2003048298A2 (en) * | 2001-12-05 | 2003-06-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof |
US20050085432A1 (en) * | 2001-12-26 | 2005-04-21 | Aviva Lapidot | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
EP1465982A4 (de) * | 2002-01-25 | 2006-06-07 | Gamida Cell Ltd | Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
EP1485075A4 (de) * | 2002-02-20 | 2006-04-26 | Dyax Corp | Mhc-peptid-komplexbindende liganden |
AU2003214614B2 (en) * | 2002-03-18 | 2008-11-20 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
WO2003079967A2 (en) * | 2002-03-26 | 2003-10-02 | Nanocyte Inc. | Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue |
US20040121442A1 (en) * | 2002-05-05 | 2004-06-24 | Ilan Chet | Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof |
WO2004012762A2 (en) | 2002-08-01 | 2004-02-12 | Yeda Research And Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
US7267981B2 (en) | 2002-10-07 | 2007-09-11 | Technion Research & Development Foundation Ltd. | Human foreskin fibroblasts for culturing ES cells |
EP1554584B1 (de) * | 2002-10-11 | 2008-05-07 | Sentina Biotechnology Incorporated | Verfahren zum nachweis von brustkrebs |
AU2003284968A1 (en) * | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
WO2004040252A2 (en) | 2002-10-30 | 2004-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Molecules and methods using same for measuring non-transferrin bound iron |
US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
WO2004050826A2 (en) * | 2002-11-29 | 2004-06-17 | Technion Research & Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
US7491699B2 (en) * | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
EP2338896B1 (de) | 2002-12-12 | 2015-02-11 | R.B.T. (Rakuto Bio Technologies) Ltd. | Verwendung von Ligninperoxidase zur Haut- und Haaraufhellung |
ES2571355T3 (es) | 2002-12-16 | 2016-05-24 | Technion Res & Dev Foundation | Sistema de cultivo sin células alimentadoras ni xenocontaminantes para células madre embrionarias humanas |
WO2004060135A2 (en) | 2003-01-02 | 2004-07-22 | Rappaport Family Institute For Research In The Medical Sciences | Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients |
EP1583713B1 (de) | 2003-01-07 | 2009-03-25 | Ramot at Tel Aviv University Ltd. | Peptidenanostrukturen die fremdmaterial enthalten, und verfahren zur herstellung derselben |
EP1599598A4 (de) | 2003-03-04 | 2007-08-08 | Yeda Res & Dev | Pon-polypeptide, diese codierende polynukleotide und zusammensetzungen und verfahren unter verwendung davon |
CA2517959A1 (en) * | 2003-03-07 | 2004-09-16 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
EP2330132B1 (de) | 2003-04-04 | 2013-08-14 | Yeda Research and Development Co. Ltd. | Antikörper gegen MMP2 oder MMP9 und pharmazeutische Zusammensetzungen davon zur Hemmung deren Metalloproteinaktivität |
CA2520023C (en) | 2003-04-08 | 2013-02-05 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to sdf-1 and methods of generating and using same |
FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US7554007B2 (en) | 2003-05-22 | 2009-06-30 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants |
AU2005234725B2 (en) * | 2003-05-22 | 2012-02-23 | Evogene Ltd. | Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby |
CA2978152C (en) | 2003-05-22 | 2021-01-26 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby |
US20050020499A1 (en) * | 2003-05-27 | 2005-01-27 | Bar Ilan University | Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method |
US8129514B2 (en) * | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
US7498428B2 (en) * | 2003-06-19 | 2009-03-03 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
JP5137400B2 (ja) | 2003-06-30 | 2013-02-06 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
CN101076585A (zh) * | 2003-08-14 | 2007-11-21 | 生物平衡公司 | 细菌株系、包括该细菌株系的组合物和其益生菌用途 |
US7625707B2 (en) | 2003-10-02 | 2009-12-01 | Ramot At Tel Aviv University Ltd. | Antibacterial agents and methods of identifying and utilizing same |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
ATE509034T1 (de) | 2003-10-07 | 2011-05-15 | Yeda Res & Dev | Antikörper gegen nik, deren herstellung und verwendung |
JP2007508837A (ja) * | 2003-10-23 | 2007-04-12 | ファイザー・プロダクツ・インク | 歯周疾患のためのワクチン |
CA2547459C (en) | 2003-11-30 | 2013-10-08 | Yeda Research And Development Co. Ltd | Modulators of nik-siva complex formation for treating immune disorders |
WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
US20100221233A1 (en) * | 2003-12-15 | 2010-09-02 | University Of South Florida | Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
EP1722834B1 (de) | 2003-12-22 | 2012-06-27 | Regentis Biomaterials Ltd. | Matrix mit natürlich vorkommendem vernetztem proteingerüst |
EP2251695B1 (de) | 2003-12-23 | 2013-07-17 | Mount Sinai Hospital Corporation | Mit endometrialer krankheit assoziierte marker |
US8007847B2 (en) * | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
US7423139B2 (en) * | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
US20060147946A1 (en) * | 2004-01-27 | 2006-07-06 | Pinchas Akiva | Novel calcium channel variants and methods of use thereof |
AU2005219441A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | ALK7 and myostatin inhibitors and uses thereof |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
WO2005115394A2 (en) * | 2004-04-20 | 2005-12-08 | New York University School Of Medicine | Prenyl-electrostatic switch, and methods of use |
EP2336330B1 (de) | 2004-06-14 | 2018-01-10 | Evogene Ltd. | An der Entwicklung von Pflanzenfasern beteiligte Polynukleotide und Polypeptide sowie Verfahren zur Verwendung davon |
US8680062B2 (en) * | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
US20090156471A1 (en) * | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
WO2006013552A2 (en) * | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
US7786086B2 (en) | 2004-09-08 | 2010-08-31 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
EP1799812A4 (de) * | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen |
EP3088528B1 (de) | 2004-09-29 | 2019-07-03 | Collplant Ltd. | Kollagenproduzierende pflanzen und verfahren zur erzeugung und verwendung davon |
AU2005288527B9 (en) * | 2004-09-29 | 2011-07-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Recombinant human T2 RNase and uses thereof |
US7781402B2 (en) * | 2004-10-12 | 2010-08-24 | Closed Loop Therapies Ltd. | Methods and implantable devices for treating supraventricular arrhythmias |
US20060134680A1 (en) * | 2004-12-22 | 2006-06-22 | Alexander Kotlyar | Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof |
JP2008529325A (ja) * | 2005-01-16 | 2008-07-31 | ズランゴー リミテッド | 通信ネットワークシステムおよびそれを使用するための方法 |
JP2008527563A (ja) * | 2005-01-16 | 2008-07-24 | ズランゴー リミテッド | アイコニック通信 |
WO2006080021A2 (en) | 2005-01-31 | 2006-08-03 | Realbio Technologies Ltd. | Multistep reaction lateral flow capillary device |
JP4992091B2 (ja) | 2005-02-17 | 2012-08-08 | ハダシット メディカル リサーチ サービシーズ アンド デベロップメント リミテッド | 子宮内膜症を治療するためのビスホスホネート |
EP1871402B1 (de) | 2005-02-25 | 2017-07-26 | State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (A.R.O.), Volcani Center | Weintraubezellkultur zur behandlung von entzündungen |
US7695927B2 (en) * | 2005-03-18 | 2010-04-13 | Detroit R & D | Detection of hypertension using glucuronidated metabolic products |
WO2006109312A2 (en) * | 2005-04-15 | 2006-10-19 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease |
US8834862B2 (en) * | 2005-04-19 | 2014-09-16 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent |
WO2006126208A2 (en) | 2005-05-26 | 2006-11-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
WO2006134602A2 (en) | 2005-06-16 | 2006-12-21 | Ramot At Tel Aviv University Ltd. | Isolated cells and populations comprising same for the treatment of cns diseases |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
WO2007007325A2 (en) | 2005-07-07 | 2007-01-18 | Fulcrum Sp Ltd. | Sp1 polypeptides, modified sp1 polypeptides and uses thereof |
CA2614531C (en) * | 2005-07-07 | 2015-06-16 | Avraham Hochberg | Nucleic acid agents for downregulating h19, and methods of using same |
AU2006271181B2 (en) | 2005-07-18 | 2012-07-12 | Protalix Ltd. | Mucosal or enteral administration of biologically active macromolecules |
US8642330B2 (en) * | 2005-08-08 | 2014-02-04 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
WO2007023491A2 (en) | 2005-08-24 | 2007-03-01 | Yeda Research And Development Co. Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
US8476070B2 (en) | 2005-08-29 | 2013-07-02 | Technion Research & Development Foundation Limited | Media for culturing stem cells |
ATE466079T1 (de) | 2005-09-22 | 2010-05-15 | Yissum Res Dev Co | Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs |
US10004828B2 (en) * | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
US20070087437A1 (en) * | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
MX350551B (es) | 2005-10-24 | 2017-09-08 | Evogene Ltd | Polipeptidos aislados, polinucleotidos que los codifican, plantas transgenicas que expresan los mismos y metodos para usarlos. |
US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
KR20080072748A (ko) | 2005-11-29 | 2008-08-06 | 가미다-셀 리미티드 | 줄기세포 귀소 및 생착을 향상시키는 방법 |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
EP1977312A2 (de) | 2006-01-16 | 2008-10-08 | Zlango Ltd. | Bildzeichenkommunikation |
EP1982450A2 (de) * | 2006-01-16 | 2008-10-22 | Zlango Ltd. | Kommunikationsnetzsystem und verfahren zu seiner verwendung |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
WO2007092252A2 (en) | 2006-02-03 | 2007-08-16 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
WO2007091254A1 (en) | 2006-02-06 | 2007-08-16 | Rappaport Family Institute For Research In The Medical Sciences | Methods and kit for diagnosing t1dm |
CA2642984A1 (en) * | 2006-02-22 | 2007-09-07 | The Texas A & M University System | Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use |
WO2007102146A2 (en) | 2006-03-06 | 2007-09-13 | Zetiq Technologies Ltd. | Methods and compositions for identifying a cell phenotype |
MX2008012085A (es) | 2006-03-23 | 2009-01-22 | Pluristem Ltd | Metodos para expansion de celulas y usos de celulas y medios acondicionados producidos de esta manera para terapia. |
EP2004858A4 (de) | 2006-03-28 | 2009-12-09 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Verfahren und kits zur bestimmung einer veranlagung zur warfarin-resistenz |
EP2010567A2 (de) * | 2006-04-07 | 2009-01-07 | The Government of the United States of America as Represented by The Department of Health and Human Services | Antikörperzusammensetzungen und verfahren zur behandlung von neoplasien |
ZA200810677B (en) * | 2006-05-19 | 2010-03-31 | Teva Pharma | Fusion proteins, uses thereof and processes for producing same |
US20070281883A1 (en) * | 2006-06-05 | 2007-12-06 | Hanna Rosenfeld | Development of follicle stimulating hormone agonists and antagonists in fish |
WO2008010228A2 (en) | 2006-07-20 | 2008-01-24 | Yeda Research And Development Co. Ltd. | Photosyntheticorganisms and compositions and methods of generating same |
EP2064319B1 (de) | 2006-08-28 | 2017-02-22 | Yeda Research and Development Co. Ltd. | Verfahren zur erzeugung von glia- und neuronalen zellen und verwendung davon für die behandlung medizinischer leiden des zns |
US7888059B2 (en) * | 2006-10-05 | 2011-02-15 | Yeda Research And Development Co. Ltd. | Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same |
EP2079860B1 (de) | 2006-10-05 | 2013-08-07 | Technion Research & Development Foundation Ltd. | Mikroröhrchen und herstellungsverfahren dafür |
CA2703795A1 (en) | 2006-10-27 | 2008-05-02 | Mount Sinai Hospital | Endometrial phase or endometrial cancer biomarkers |
US20080131954A1 (en) * | 2006-11-30 | 2008-06-05 | Canon U.S. Life Sciences, Inc. | Method of Separating Target DNA from Mixed DNA |
MX349479B (es) | 2006-12-20 | 2017-07-31 | Evogene Ltd | Polinucleotidos y polipeptidos involucrados en el desarrollo de fibra vegetal y metodos de uso. |
ATE548454T1 (de) * | 2007-01-16 | 2012-03-15 | Yissum Res Dev Co | Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis |
WO2008093331A1 (en) * | 2007-01-29 | 2008-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antibody conjugates for circumventing multi-drug resistance |
EP2117616A2 (de) | 2007-01-31 | 2009-11-18 | Technion Research & Development Foundation Ltd. | Elektrisch gesponnene gerüste und verfahren zu ihrer erzeugung und verwendung |
CA2676932C (en) | 2007-02-01 | 2015-11-24 | Technion Research & Development Foundation Ltd. | Albumin fibers and fabrics and methods of generating and using same |
ES2662036T3 (es) | 2007-02-28 | 2018-04-05 | Yeda Research And Development Company Limited | Secuencias que se dirigen al núcleo |
EP2514766A3 (de) | 2007-03-29 | 2013-06-05 | Technion Research & Development Foundation Ltd. | Antikörper, Verfahren und Kits zur Diagnose und Behandlung von Melanomen |
JP2010523104A (ja) | 2007-04-02 | 2010-07-15 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | ガン細胞検出方法ならびにガン疾患の診断およびガン疾患の処置のモニタリングのためのその使用 |
WO2008122980A2 (en) * | 2007-04-09 | 2008-10-16 | Evogene Ltd. | Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants |
US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
PT2144633E (pt) | 2007-04-23 | 2014-10-27 | Deliversir Ltd | Um sistema para a administração de agentes terapêuticos em células vivas e núcleos de células |
WO2008132753A2 (en) | 2007-05-01 | 2008-11-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for detecting fetal cells in the maternal blood |
EP2529754A1 (de) | 2007-05-03 | 2012-12-05 | Agency For Science, Technology And Research (A*star) | An ein intrazellulares PRL-1- oder PRL-3-Polypeptid bindende Antikörper |
SG187447A1 (en) | 2007-05-07 | 2013-02-28 | Protalix Ltd | Large scale disposable bioreactor |
US20100256464A1 (en) * | 2007-05-14 | 2010-10-07 | Dr. Susan Love Research Foundation | Device for determining risk of developing breast cancer and method thereof |
WO2009007980A1 (en) | 2007-07-11 | 2009-01-15 | Yeda Research And Development Co. Ltd. | Nucleic acid construct systems capable of diagnosing or treating a cell state |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
CA2696833A1 (en) | 2007-07-15 | 2009-01-22 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
AU2008278654B2 (en) | 2007-07-24 | 2014-06-05 | Evogene Ltd. | Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same |
ES2402334T3 (es) * | 2007-08-02 | 2013-04-30 | Gilead Biologics, Inc | Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis |
MX2010001657A (es) | 2007-08-15 | 2010-03-15 | Yeda Res & Dev | Reguladores de mmp-9 y usos de los mismos. |
EP2195650B1 (de) | 2007-09-12 | 2016-07-06 | Yeda Research And Development Company Ltd. | Verfahren zur behandlung von tumoren an immunprivilegierten stellen |
EP2200622B2 (de) | 2007-09-19 | 2015-07-29 | Pluristem Ltd. | Haftende zellen von fett- oder plazenta-gewebe und ihre verwendung in der therapie |
ES2620487T3 (es) | 2007-10-19 | 2017-06-28 | Rappaport Family Institute For Research In The Medical Sciences | Composiciones que comprenden semaforinas para uso en el tratamiento del cáncer |
US8431158B2 (en) | 2007-11-26 | 2013-04-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions comprising fibrous polypeptides and polysaccharides |
AU2008344935C1 (en) | 2007-12-27 | 2016-07-14 | Evogene Ltd. | Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants |
US20110052501A1 (en) * | 2008-01-31 | 2011-03-03 | Liat Dassa | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
CA2618163A1 (en) | 2008-02-07 | 2009-08-07 | K. W. Michael Siu | Head and neck cancer biomarkers |
WO2009104176A2 (en) | 2008-02-21 | 2009-08-27 | Technion Research & Development Foundation Ltd. | Methods of attaching a molecule-of-interest to a microtube |
WO2009125394A1 (en) * | 2008-04-09 | 2009-10-15 | Technion Research & Development Foundation Ltd. | Anti human immunodeficiency antibodies and uses thereof |
EP2274153B1 (de) * | 2008-04-10 | 2012-07-04 | Objet Ltd. | System und verfahren für dreidimensionalen modelldruck |
PL2288376T3 (pl) | 2008-04-18 | 2016-07-29 | Collplant Ltd | Sposoby generowania i wykorzystywania prokolagenu |
CA2721372A1 (en) | 2008-04-21 | 2009-10-29 | Danziger Innovations Ltd. | Plant viral expression vectors and use of same for generating genotypic variations in plant genomes |
CN102149729B (zh) | 2008-04-25 | 2014-08-20 | 戴埃克斯有限公司 | 针对fcrn的抗体及其用途 |
EP2116618A1 (de) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnose und Behandlung des Kawasaki-Syndroms |
WO2009141824A2 (en) * | 2008-05-22 | 2009-11-26 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny |
WO2009144720A1 (en) | 2008-05-27 | 2009-12-03 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
ES2688945T3 (es) | 2008-05-28 | 2018-11-07 | Ramot At Tel-Aviv University Ltd. | Células madre mesenquimales para el tratamiento de enfermedades del SNC |
EP2304439A4 (de) | 2008-05-29 | 2012-07-04 | Nuclea Biotechnologies Llc | Anti-phospho-akt-antikörper |
EP2326419B1 (de) | 2008-06-29 | 2021-04-07 | Realbio Technologies Ltd. | Flüssigkeitstransfervorrichtung, die besonders gut als einfangvorrichtung in einem biologischen assayverfahren geeignet ist |
EP2657342B1 (de) | 2008-08-08 | 2015-11-18 | Genisphere, LLC | Vor Nukleaseabbruch geschützte DNA-Dendrimere |
CN102176914B (zh) | 2008-08-08 | 2014-12-17 | 新加坡科技研究局 | 用于诊断和治疗癌症的vhz |
AU2009283785B2 (en) | 2008-08-18 | 2016-01-28 | Evogene Ltd. | Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants |
AU2009288781B2 (en) | 2008-09-02 | 2015-01-29 | Pluri Biotech Ltd | Adherent cells from placenta tissue and use thereof in therapy |
US8367392B2 (en) * | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
US20110305682A1 (en) | 2008-09-11 | 2011-12-15 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and Methods for Treating S. Pneumonia Infection |
BRPI0919020A2 (pt) | 2008-09-12 | 2017-08-22 | Univ South Florida | Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris |
ES2690348T3 (es) | 2008-09-24 | 2018-11-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Péptidos y composiciones para la prevención de la adhesión celular y métodos de uso de los mismos |
CA2736729A1 (en) | 2008-09-29 | 2010-04-01 | Ben Gurion University Of The Negev Research And Development Authority | Amyloid beta-peptides and methods of use thereof |
US8921658B2 (en) | 2008-10-30 | 2014-12-30 | Evogene Ltd. | Isolated polynucleotides encoding a MAP65 polypeptide and methods of using same for increasing plant yield |
US20110229892A1 (en) | 2008-11-17 | 2011-09-22 | Yehuda G Assaraf | Method for predicting a patient's responsiveness to anti-folate therapy |
WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
WO2010061383A1 (en) | 2008-11-26 | 2010-06-03 | Biodalia Microbiological Technologies Ltd. | A method of in-situ enrichment of foods with fructan |
WO2010064231A1 (en) | 2008-12-02 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of analyzing a-i rna editing and nucleic acid constructs capable of same |
US20120014927A1 (en) | 2008-12-03 | 2012-01-19 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for determining predisposition to cancer |
EP2373301B1 (de) | 2008-12-05 | 2013-11-06 | Yeda Research and Development Co. Ltd. | Verfahren zur diagnose der motorischen nervenerkrankungen |
WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
AR074925A1 (es) | 2008-12-29 | 2011-02-23 | Evogene Ltd | Polinucleotidos, polipeptidos codificados, y metodos para utilizarlos para modular la tolerancia al estres abiotico, biomasa y/o rendimiento en plantas que los expresan |
EP2808402A3 (de) | 2008-12-29 | 2015-03-25 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Verfahren zur Vorhersage des Ansprechens auf Interferonbehandlung |
CA2967412C (en) | 2008-12-29 | 2018-07-17 | Tel Hashomer Medical Research, Infrastructure And Services Ltd. | Peptides and compositions for prevention of cell adhesion and methods of using same |
WO2010076794A1 (en) | 2008-12-31 | 2010-07-08 | Technion Research & Development Foundation Ltd. | Method of denitrifying brine and systems capable of same |
WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
IL196820A0 (en) | 2009-02-01 | 2009-11-18 | Yissum Res Dev Co | Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells |
US8691760B2 (en) | 2009-02-02 | 2014-04-08 | Ramot At Tel-Aviv University | Peptides, pharmaceutical compositions comprising same and uses thereof |
WO2010089707A1 (en) | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
WO2010097793A2 (en) | 2009-02-26 | 2010-09-02 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Isolated populations of renal stem cells and methods of isolating and using same |
MX342016B (es) | 2009-03-02 | 2016-09-09 | Evogene Ltd | Polinucleotidos y polipeptidos aislados, y metodos para usarlos para incrementar el rendimiento de una planta y/o caracteristicas agricolas. |
DK2406279T3 (en) | 2009-03-09 | 2016-04-25 | Univ Ramot | Compositions for prevention and treatment of neurodegenerative diseases |
WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
DK2414542T3 (da) | 2009-03-30 | 2017-11-27 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose |
AU2010231514A1 (en) | 2009-04-01 | 2011-11-03 | Rappaport Family Institute For Research In The Medical Sciences | A method of regulating proliferation and differentiation of keratinocytes |
WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
WO2010125571A1 (en) | 2009-04-30 | 2010-11-04 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anti ceacam1 antibodies and methods of using same |
CN102576024B (zh) | 2009-05-19 | 2016-10-26 | 泽蒂克科技有限公司 | 宫颈癌细胞和/或组织的鉴别染色的试剂盒和方法 |
CN102639146A (zh) | 2009-05-27 | 2012-08-15 | 耶达研究及发展有限公司 | 蛋白酶体抑制剂及其用途 |
US20120078163A1 (en) | 2009-05-27 | 2012-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
WO2010137013A1 (en) | 2009-05-27 | 2010-12-02 | Ramot At Tel Aviv University Ltd. | Crystallized photosystem i units from the pea plant and their use in solid state devices |
WO2010137020A1 (en) | 2009-05-28 | 2010-12-02 | Yeda Research And Development Co. Ltd. | Methods of treating inflammation |
EP3238534B1 (de) | 2009-06-10 | 2019-11-13 | Evogene Ltd. | Isolierte polynukleotide und polypeptide sowie verfahren zur verwendung davon zur erhöhung der stickstoffverwendungseffizienz, des ertrags, der wachstumsrate, der stärke, der biomasse, des ölgehalts und/oder der abiotischen stresstoleranz |
IN2012DN00715A (de) | 2009-06-24 | 2015-06-19 | Health Corp Rambam | |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
WO2011004379A1 (en) | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
ES2753986T3 (es) | 2009-07-21 | 2020-04-15 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Un método de diagnóstico de cáncer |
GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
EP2467470A2 (de) | 2009-08-17 | 2012-06-27 | Technion Research & Development Foundation Ltd. | Pericytvorläuferzellen sowie verfahren zu ihrer herstellung und verwendung |
CA2770276A1 (en) | 2009-08-21 | 2012-02-24 | Beeologics, Inc. | Preventing and curing beneficial insect diseases via plant transcribed molecules |
US20110076272A1 (en) * | 2009-08-21 | 2011-03-31 | Victoria Smith | Therapeutic methods and compositions |
WO2011022709A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vitro screening assays |
EP2467396A4 (de) | 2009-08-21 | 2012-12-26 | Gilead Biologics Inc | Katalytische domänen aus lysyl-oxidase und loxl2 |
CN102711820A (zh) * | 2009-08-21 | 2012-10-03 | 吉联亚生物科技有限公司 | 治疗肺纤维化疾病的方法和组合物 |
US20110044907A1 (en) * | 2009-08-21 | 2011-02-24 | Derek Marshall | In vivo screening assays |
US9642817B2 (en) | 2009-08-27 | 2017-05-09 | Technion Research & Development Foundation Limited | Liposomal compositions and uses of same |
US9610331B2 (en) | 2009-09-08 | 2017-04-04 | Yeda Research And Development Co. Ltd. | Methods for hematopoietic precursor mobilization |
EP2475784A1 (de) | 2009-09-08 | 2012-07-18 | Ramot at Tel-Aviv University Ltd. | Verfahren zur diagnose von amyotropher lateralsklerose (als) |
WO2011030329A1 (en) | 2009-09-10 | 2011-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
BR112012006005A2 (pt) | 2009-09-17 | 2017-09-19 | Univ Ramot | "peptídeos no tratamento de transtorno associados ao estresse oxidativo" |
WO2011033506A2 (en) | 2009-09-17 | 2011-03-24 | Yeda Research And Development Co. Ltd. | Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
US8735124B2 (en) | 2009-09-17 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
EP3272869B1 (de) | 2009-10-14 | 2020-06-24 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Zusammensetzungen zur bekämpfung von varroa-milben bei bienen |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
WO2011046570A1 (en) | 2009-10-16 | 2011-04-21 | The University Of Medicine And Dentistry Of New Jersey | Method for treating chronic nerve tissue injury using a cell therapy strategy |
US9476060B2 (en) | 2009-10-21 | 2016-10-25 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
IL201999A (en) | 2009-11-08 | 2017-10-31 | Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel | A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity |
WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
WO2011058557A1 (en) | 2009-11-12 | 2011-05-19 | Ramot At Tel-Aviv University Ltd. | Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes |
US20110143378A1 (en) * | 2009-11-12 | 2011-06-16 | CyVek LLC. | Microfluidic method and apparatus for high performance biological assays |
DK3633025T3 (da) | 2009-11-12 | 2022-12-12 | Technion Res & Dev Foundation | Dyrkningsmedier, cellekulturer og metoder til dyrkning af pluripotente stamceller i en udifferentieret tilstand |
WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
US9700889B2 (en) | 2009-11-23 | 2017-07-11 | Cyvek, Inc. | Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results |
US9651568B2 (en) | 2009-11-23 | 2017-05-16 | Cyvek, Inc. | Methods and systems for epi-fluorescent monitoring and scanning for microfluidic assays |
US9500645B2 (en) | 2009-11-23 | 2016-11-22 | Cyvek, Inc. | Micro-tube particles for microfluidic assays and methods of manufacture |
US10065403B2 (en) | 2009-11-23 | 2018-09-04 | Cyvek, Inc. | Microfluidic assay assemblies and methods of manufacture |
JP5701894B2 (ja) | 2009-11-23 | 2015-04-15 | サイヴェク・インコーポレイテッド | アッセイを行う方法及び装置 |
US9759718B2 (en) | 2009-11-23 | 2017-09-12 | Cyvek, Inc. | PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use |
US9855735B2 (en) | 2009-11-23 | 2018-01-02 | Cyvek, Inc. | Portable microfluidic assay devices and methods of manufacture and use |
WO2013134745A1 (en) | 2012-03-08 | 2013-09-12 | Cyvek, Inc | Portable microfluidic assay devices and methods of manufacture and use |
EP2504472A1 (de) | 2009-11-24 | 2012-10-03 | Collplant Ltd. | Verfahren zur erzeugung von kollagenfasern |
NZ600651A (en) | 2009-11-30 | 2014-07-25 | Pluristem Ltd | Adherent cells from placenta and use of same in disease treatment |
WO2011067745A2 (en) | 2009-12-06 | 2011-06-09 | Rosetta Green Ltd. | Compositions and methods for enhancing plants resistance to abiotic stress |
EP2862929B1 (de) | 2009-12-09 | 2017-09-06 | Quark Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur Behandlung von Erkrankungen, Störungen oder Läsionen des ZNS |
AU2010337936B2 (en) | 2009-12-28 | 2016-06-23 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
EP3785712A1 (de) | 2009-12-29 | 2021-03-03 | Gamida-Cell Ltd. | Verfahren zur steigerung der proliferation und aktivität natürlicher killerzellen |
US9567605B2 (en) | 2010-01-05 | 2017-02-14 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
US20130052165A1 (en) | 2010-01-12 | 2013-02-28 | Livnat Bangio | Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby |
CA2787311C (en) | 2010-01-27 | 2017-08-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
RU2549684C2 (ru) | 2010-02-04 | 2015-04-27 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
US9410131B2 (en) | 2010-02-11 | 2016-08-09 | Yeda Research And Development Co. Ltd. | Enzymatic systems for carbon fixation and methods of generating same |
WO2011104708A2 (en) | 2010-02-24 | 2011-09-01 | Ben Gurion University Of The Negev Research And Development Authority | Methods for inhibiting necrosis |
WO2011107939A1 (en) | 2010-03-01 | 2011-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting efficacy of an anti-vegfa treatment for solid tumors |
WO2011107994A1 (en) | 2010-03-04 | 2011-09-09 | Yeda Research And Development Co. Ltd. | Methods of measuring protein stability |
WO2011112570A1 (en) | 2010-03-08 | 2011-09-15 | Monsanto Technology Llc | Polynucleotide molecules for gene regulation in plants |
US9267142B2 (en) | 2010-03-08 | 2016-02-23 | Yeda Research And Development Co. Ltd. | Recombinant protein production in heterologous systems |
WO2011111050A2 (en) | 2010-03-11 | 2011-09-15 | Jacob Edrei | Methods of generating hydrogen |
EP2556085A2 (de) | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Proteaseaktivierbare, porenbildende polypeptide |
WO2011128897A1 (en) | 2010-04-12 | 2011-10-20 | Technion Research & Development Foundation Ltd. | Populations of pancreatic progenitor cells and methods of isolating and using same |
US9458438B2 (en) | 2010-04-12 | 2016-10-04 | Ben Gurion University Of The Negev Research And Development Authority | Sulfotransferase of a red microalga and uses thereof |
US9518988B2 (en) | 2010-04-18 | 2016-12-13 | Yeda Research And Development Co. Ltd. | Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseases |
CA2797200C (en) | 2010-04-28 | 2020-03-31 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics |
US20130053277A1 (en) | 2010-05-04 | 2013-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of identifying inhibitors of polypeptides-of-interest |
EP2566500B1 (de) | 2010-05-05 | 2017-04-12 | Rappaport Family Institute for Research in the Medical Sciences | Ccl1 zur verwendung für therapeutische zwecke |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
EP2569417B1 (de) | 2010-05-13 | 2018-04-18 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Isolierte populationen adulter nierenzellen sowie verfahren zu ihrer isolierung und verwendung |
US9624285B2 (en) | 2010-06-03 | 2017-04-18 | Ramot a Tel-Aviv University Ltd. | Methods of treating diabetes and compositions capable of same |
WO2011154940A1 (en) | 2010-06-07 | 2011-12-15 | Osnat Ashur-Fabian | Methods and kits for diagnosing conditions related to hypoxia |
US9187787B2 (en) | 2010-06-16 | 2015-11-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of diagnosing and treating cancer |
BR112012032126A2 (pt) | 2010-06-16 | 2017-10-17 | Futuragene Israel Ltd Empresa Isralense | polinucleotídeo isolado, estrutura de ácido nucléico, sistema de estrutura de ácido nucléico, polipeptídeo isolado, planta, composição inseticida, e método para controlar ou exterminar um inseto |
US9512188B2 (en) | 2010-07-12 | 2016-12-06 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Isolated polynucleotides and methods and plants using same for regulating plant acidity |
EP2593480A2 (de) | 2010-07-15 | 2013-05-22 | Technion Research & Development Foundation Ltd. | Antikörper mit t-zell-rezeptorähnlicher spezifität gegenüber nativen komplexen der mhc-klasse ii und diabetes-assoziierten autoantigenen peptiden |
EP2593551B1 (de) | 2010-07-15 | 2016-09-14 | Technion Research & Development Foundation Ltd. | Isolierte hochaffine einheiten mit t-zell-rezeptorähnlicher spezifität gegenüber nativen komplexen der mhc-klasse ii und autoantigenen gad-peptiden |
CN103108955B (zh) | 2010-07-15 | 2015-11-25 | 工业研究与发展基金会有限公司 | 用于提高植物中非生物胁迫耐受性的核酸构建体 |
WO2012011113A2 (en) | 2010-07-22 | 2012-01-26 | Shai Yarkoni | Regulatory immune cells with enhanced targeted cell death effect |
WO2012014207A2 (en) | 2010-07-27 | 2012-02-02 | Technion Research & Development Foundation Ltd. | Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles |
US9144585B2 (en) | 2010-07-27 | 2015-09-29 | Technion Research & Development Foundation Limited | Isolated mesenchymal progenitor cells and extracellular matrix produced thereby |
WO2012014208A2 (en) | 2010-07-27 | 2012-02-02 | Yeda Research And Development Co. Ltd. | Methods and systems for assessing clonality of cell cultures |
EP2600885A2 (de) | 2010-08-04 | 2013-06-12 | Ramot at Tel Aviv University, Ltd. | Verfahren zur behandlung von autoimmunerkrankungen des zentralnervensystems (zns) und neurodegenerativen erkrankungen |
CA2807209C (en) | 2010-08-16 | 2019-09-17 | Mount Sinai Hospital | Markers of the male urogenital tract |
WO2012025914A1 (en) | 2010-08-22 | 2012-03-01 | Ramot At Tel-Aviv University Ltd. | Induced pluripotent stem cells derived from human pancreatic beta cells |
WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
AR082530A1 (es) | 2010-08-30 | 2012-12-12 | Evogene Ltd | Polinucleotidos y polipeptidos aislados, y metodos para utilizarlos para aumentar la eficacia en el uso de nitrogeno, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o tolerancia al estres abiotico |
WO2012032510A1 (en) | 2010-09-07 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Primers for amplifying dna and methods of selecting same |
SG10202109393RA (en) | 2010-09-07 | 2021-10-28 | Technion Res & Dev Foundation | Novel Methods And Culture Media For Culturing Pluripotent Stem Cells |
US20130164288A1 (en) | 2010-09-07 | 2013-06-27 | Protalix Ltd. | Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease |
WO2012032519A2 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of diagnosing parkinson's disease |
ES2589678T3 (es) | 2010-09-08 | 2016-11-15 | Yeda Research And Development Co. Ltd. | Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma |
WO2012032525A2 (en) | 2010-09-08 | 2012-03-15 | Yeda Research And Development Co. Ltd. | An immunosuppressive drug combination for a stable and long term engraftment |
WO2012035539A1 (en) | 2010-09-15 | 2012-03-22 | Ramot At Tel-Aviv University Ltd. | Methods of expanding and redifferentiating islet beta cells |
WO2012038956A1 (en) | 2010-09-20 | 2012-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
EP3075396A1 (de) | 2010-10-17 | 2016-10-05 | Yeda Research and Development Co. Ltd. | Verfahren und zusammensetzungen zur behandlung von insulinassoziierten erkrankungen |
WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
US20130216603A1 (en) | 2010-10-27 | 2013-08-22 | Nanocyte (Israel) Ltd. | Pharmaceutical compositions and delivery devices comprising stinging cells or capsules |
WO2012056455A1 (en) | 2010-10-28 | 2012-05-03 | Yeda Research And Development Co. Ltd. | Methods of generating antibodies to metalloenzymes |
CA2815927A1 (en) | 2010-11-03 | 2012-05-10 | Yissum Research Development Company Of The Hebrew University Of Jerusale M Ltd. | Transgenic plants with improved saccharification yields and methods of generating same |
EP2635105B1 (de) | 2010-11-04 | 2017-12-20 | Ben-Gurion University of The Negev Research and Development Authority | Acyl-coa: diacylglyzerin-acyltransferase-1-ähnliches gen (ptdgat1) und verwendungen davon |
CA2817830A1 (en) | 2010-11-15 | 2012-05-24 | Ramot At Tel Aviv University Ltd. | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
US10117895B2 (en) | 2010-11-17 | 2018-11-06 | Ben-Gurion University Of The Negev Research And Development Authority | T-cell therapy to neurodegenerative diseases |
JP6139410B2 (ja) | 2010-12-02 | 2017-05-31 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 角膜細胞の作製方法および該角膜細胞を含む細胞集団 |
AU2011253984A1 (en) | 2010-12-07 | 2012-06-28 | Biobalance Llc | Method For Identifying E. Coli M-17 |
WO2012081029A1 (en) | 2010-12-15 | 2012-06-21 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
CA2821257C (en) | 2010-12-22 | 2020-12-22 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing abiotic stress tolerance, yield, growth rate, vigor, biomass, oil content, and/or nitrogen use efficiency of plants |
SG191768A1 (en) | 2010-12-28 | 2013-08-30 | Kamedis Ltd | Plant extracts for the treatment and prevention of infections |
PT3272861T (pt) | 2011-01-20 | 2020-03-26 | Protalix Ltd | Construção de ácido nucleico para expressão de alfα-galactosidase em plantas e células de plantas |
US20130316358A1 (en) | 2011-01-31 | 2013-11-28 | Yeda Research And Development Co. Ltd. | Methods of diagnosing disease using overlap extension pcr |
US20130330349A1 (en) | 2011-02-23 | 2013-12-12 | Rappaport Family Institute For Research In The Medical Sciences | High affinity molecules capable of binding a type a plexin receptor and uses of same |
CN103597078B (zh) | 2011-03-02 | 2016-12-14 | 富途锐基尼以色列有限公司 | 具有功能失调的t3ss蛋白的抗菌性转基因植物 |
US9365828B2 (en) | 2011-03-03 | 2016-06-14 | Ramot At Tel-Aviv University Ltd. | Genetically modified muscle cells which express neurotrophic factors |
AU2012226398B9 (en) | 2011-03-06 | 2017-04-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
US9061006B2 (en) | 2011-03-08 | 2015-06-23 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (PKU) |
WO2012123938A1 (en) | 2011-03-17 | 2012-09-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
JP2014510084A (ja) | 2011-03-17 | 2014-04-24 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法 |
KR101835917B1 (ko) | 2011-03-22 | 2018-03-07 | 플루리스템 리미티드 | 방사선 또는 화학적 손상을 치료하는 방법들 |
CA2830533C (en) | 2011-03-22 | 2020-02-18 | Cyvek, Inc. | Microfluidic devices and methods of manufacture and use |
WO2012127475A1 (en) | 2011-03-24 | 2012-09-27 | Neurim Pharmaceuticals (1991) Ltd. | Neuroprotective peptides |
WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
WO2012137202A1 (en) | 2011-04-05 | 2012-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci) |
US8728758B2 (en) | 2011-04-06 | 2014-05-20 | Ramot At Tel-Aviv University Ltd. | Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
CA2832812C (en) | 2011-04-15 | 2017-12-05 | Pluristem Ltd. | Methods and systems for harvesting cells |
BR122020018204B1 (pt) | 2011-05-03 | 2021-11-03 | Evogene Ltd | Método para aumentar o rendimento, biomassa, taxa de crescimento, tolerância ao estresse abiótico e/ou eficiência no uso de nitrogênio de uma planta |
US9192670B2 (en) | 2011-05-04 | 2015-11-24 | Ramot At Tel-Aviv University Ltd. | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease |
WO2012153333A1 (en) | 2011-05-09 | 2012-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Regeneration and repair of mesenchymal tissue using amelogenin |
WO2012153336A2 (en) | 2011-05-12 | 2012-11-15 | Rakuto Bio Technologies Ltd. | Methods and device for lightening skin complexion |
WO2012156976A1 (en) | 2011-05-16 | 2012-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of producing artemisinin in non-host plants and vectors for use in same |
WO2012160526A2 (en) | 2011-05-23 | 2012-11-29 | Ofir Menashe | Formulations of microorganism comprising particles and uses of same |
CA2836503C (en) | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
AU2012264385B2 (en) | 2011-05-31 | 2018-06-28 | Hutchison Biofilm Medical Solutions Limited | Dispersion and detachment of cell aggregates |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
CA2837527C (en) | 2011-06-02 | 2019-05-28 | Dyax Corp. | Fc receptor binding proteins |
WO2012172555A1 (en) | 2011-06-14 | 2012-12-20 | Yeda Research And Development Co. Ltd. | Combination therapy to prevent dcis formation and progression to breast cancer |
KR20140058506A (ko) | 2011-06-23 | 2014-05-14 | 카이마 바이오 아그리테크 리미티드 | 부분적으로 또는 완전히 다중화된 게놈을 가지는 보통계 밀 식물 또는 이의 부분물, 이의 하이브리드와 생성물, 및 이를 생성 및 사용하는 방법 |
MX2014000791A (es) | 2011-07-20 | 2014-10-17 | Kaiima Bio Agritech Ltd | Plantas de maiz que tienen un genoma parcial o completamente multiplicado y sus usos. |
EP2550982A1 (de) | 2011-07-27 | 2013-01-30 | Technion Research & Development Foundation Ltd. | Vorrichtungen für chirurgische Anwendungen |
CN112426538A (zh) | 2011-08-04 | 2021-03-02 | 耶达研究及发展有限公司 | 微rna和包含微rna的组合物 |
US9499793B2 (en) | 2011-08-09 | 2016-11-22 | Yeda Research And Development Co. Ltd. | Downregulation of miR-7 for promotion of beta cell differentiation and insulin production |
US20140212568A1 (en) | 2011-08-14 | 2014-07-31 | Kaiimam Bio Agritech Ltd. | Durum wheat plants having a partially or fully multiplied genome and uses thereof |
WO2013035070A1 (en) | 2011-09-07 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Olfactory signature and odorant mixture having the same |
MX351226B (es) | 2011-09-08 | 2017-10-05 | Yeda Res & Dev | Celulas t con memoria central anti tercera parte, metodos para producirlas y uso de las mismas en transplante y tratamiento de enfermedades. |
ES2657552T3 (es) | 2011-09-08 | 2018-03-05 | Yeda Research And Development Co. Ltd. | Nuevos biomarcadores de riesgo para el cáncer de pulmón |
US9416363B2 (en) | 2011-09-13 | 2016-08-16 | Monsanto Technology Llc | Methods and compositions for weed control |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
MX350771B (es) | 2011-09-13 | 2017-09-15 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas. |
MX343072B (es) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Metodos y composiciones para controlar malezas. |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
UA115535C2 (uk) | 2011-09-13 | 2017-11-27 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
DK2768851T3 (en) | 2011-10-21 | 2017-09-18 | Augurex Life Sciences Corp | ANTIGENS DERIVED BY CITRULLINATED 14-3-3 AND APPLICATIONS THEREOF IN THE DIAGNOSIS OF RHEUMATOID ARTHRITIS |
US9145559B2 (en) | 2011-10-27 | 2015-09-29 | Yeda Research And Development Co. Ltd. | Methods of treating cancer |
SG11201401648RA (en) | 2011-11-03 | 2014-05-29 | Quark Pharmaceuticals Inc | Methods and compositions for neuroprotection |
WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
US9736998B2 (en) | 2011-11-23 | 2017-08-22 | Danziger Dan Flower Farm | Otomeria plants |
EP2782930B1 (de) | 2011-11-27 | 2018-07-11 | Yeda Research and Development Co. Ltd. | Verfahren zur angiogeneseregulierung und zusammensetzungen dafür |
AU2012348574A1 (en) | 2011-12-08 | 2014-07-24 | Yeda Research And Development Co. Ltd. | Mammalian fetal pulmonary cells and therapeutic use of same |
WO2013093921A1 (en) | 2011-12-20 | 2013-06-27 | Collplant Ltd. | Collagen coated synthetic polymer fibers |
EP2794107B1 (de) | 2011-12-22 | 2021-08-11 | Life Technologies Corporation | Sequenzielle lateralfluss-kapillarvorrichtung zur analytbestimmung |
JP6313219B2 (ja) | 2011-12-22 | 2018-04-18 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | T細胞/b細胞枯渇化のための特異的プロトコルを使用する安定かつ長期の生着のための併用療法 |
MX2014008083A (es) | 2011-12-28 | 2015-03-19 | Kaiima Bio Agritech Ltd | Una planta de sorgo cultivada que tiene un genoma parcial o totalmente multiplicado y usos de la misma. |
SG11201403756PA (en) | 2012-01-01 | 2014-11-27 | Qbi Entpr Ltd | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
WO2013114363A2 (en) | 2012-01-30 | 2013-08-08 | Yeda Research And Development Co.Ltd. | Antimicrobial agents |
US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
WO2013118120A2 (en) | 2012-02-06 | 2013-08-15 | Rosetta Green Ltd. | Isolated polynucleotides expressing or modulating micrornas or targets of same, transgenic plants comprising same and uses thereof in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant |
EP2814951B1 (de) | 2012-02-13 | 2019-04-03 | Gamida-Cell Ltd. | Kultivierung mesenchymaler stammzellen |
AU2013219935B2 (en) | 2012-02-14 | 2016-02-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US20150023929A1 (en) | 2012-02-19 | 2015-01-22 | Protalix Ltd. | Oral unit dosage forms and uses of same for the treatment of gaucher disease |
JP2015509366A (ja) | 2012-02-22 | 2015-03-30 | ブレインステム バイオテック リミテッド | 神経幹細胞および運動ニューロンの生成 |
EP2844744A2 (de) | 2012-02-22 | 2015-03-11 | Brainstem Biotec Ltd. | Microrns zur erzeugung von astrocyten |
US20150101074A1 (en) | 2012-03-01 | 2015-04-09 | The State of Israel, Ministry of Agriculture & Rural Development, Agriculture Research | Male sterile garlic plants, hybrid offspring of same and methods of generating and using same |
US9631028B2 (en) | 2012-03-07 | 2017-04-25 | Yeda Research And Development Co. Ltd. | Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses of same |
EP2828280B1 (de) | 2012-03-22 | 2018-05-02 | Ramot at Tel-Aviv University Ltd. | Multimere plif-peptide und verwendungen davon |
CA2868238A1 (en) | 2012-04-18 | 2013-10-24 | Ramot At Tel Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
EP2838552A4 (de) | 2012-04-19 | 2016-05-18 | Opko Biolog Ltd | Langwirkende oxyntomodulinvarianten und verfahren zur herstellung davon |
WO2013160895A1 (en) | 2012-04-24 | 2013-10-31 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
ES2627816T3 (es) | 2012-05-09 | 2017-07-31 | Yeda Research And Development Co. Ltd. | Variantes del pro-dominio de tace como inhibidor de TNF-a y su uso médico |
BR112014029274B1 (pt) | 2012-05-24 | 2022-02-15 | Mountgate Innotech (Hk) Limited | Anticorpo isolado, composição farmacêutica, uso do anticorpo, e, kit para tratar infecção rábica |
CA2873828A1 (en) | 2012-05-24 | 2013-11-28 | A.B. Seeds Ltd. | Naked dsrna for silencing target molecules in plant seeds |
EP2855507B1 (de) | 2012-06-03 | 2018-01-03 | Ben-Gurion University of The Negev Research and Development Authority | Funktionalisierte titanbindende peptide und damit beschichtete implantate |
CA2875599C (en) | 2012-06-04 | 2020-08-18 | Opko Biologics Ltd. | Pegylated oxyntomodulin variants |
WO2014006621A1 (en) | 2012-07-03 | 2014-01-09 | Nanospun Technologies Ltd. | Methods and devices for adsorption and biodegradation of petroleum |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
EP3594331A1 (de) | 2012-07-29 | 2020-01-15 | Yeda Research and Development Co. Ltd. | Verwendung des reduktiven glycinpfades zur erzeugung formatotropher und autotropher mikroorganismen |
JP6340366B2 (ja) | 2012-07-31 | 2018-06-06 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 運動ニューロン疾患を診断および処置する方法 |
DK2880151T3 (da) | 2012-08-06 | 2020-08-17 | Brainstorm Cell Therapeutics Ltd | Fremgangsmåder til frembringelse af mesenkymale stemceller, som udskiller neurotrofiske faktorer |
AR092868A1 (es) | 2012-09-03 | 2015-05-06 | A B Seeds Ltd | Metodo para mejorar la tolerancia al estres abiotico de plantas y plantas generadas mediante dicho metodo |
EP2895197B1 (de) | 2012-09-12 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | Immunpartikel, verfahren zu deren herstellung, und deren verwendung |
WO2014057490A1 (en) | 2012-10-09 | 2014-04-17 | Ramot At Tel-Aviv University Ltd. | Methods and kits for predicting prognosis of cancer using soluble mortalin in blood |
AU2013336237A1 (en) | 2012-10-22 | 2015-06-11 | Sabag-Rfa Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
WO2014064682A1 (en) | 2012-10-24 | 2014-05-01 | Yeda Research And Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
US9926564B2 (en) | 2012-10-29 | 2018-03-27 | Yeda Research And Development Co. Ltd. | Aptamers, multimeric aptamers and uses thereof |
SG10201610223PA (en) | 2012-11-20 | 2017-02-27 | Opko Biolog Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
WO2015079413A2 (en) | 2013-11-28 | 2015-06-04 | Yeda Research And Development Co. Ltd. | Synaptojanin-2 inhibitors and uses thereof |
IN2014MN02655A (de) | 2012-11-29 | 2015-08-21 | Yeda Res & Dev | |
EP2941488B1 (de) | 2013-01-01 | 2023-03-22 | Monsanto Technology LLC | Verfahren zur einfügung von dsrna in pflanzensamen zur modulation der genexpression |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
WO2014108850A2 (en) | 2013-01-09 | 2014-07-17 | Yeda Research And Development Co. Ltd. | High throughput transcriptome analysis |
CN104937412B (zh) | 2013-01-17 | 2018-05-25 | 诺威尔卢斯德克有限公司 | 用于鉴定患者特定驱动突变物的方法和系统 |
US10000737B2 (en) | 2013-02-04 | 2018-06-19 | Ramot At Tel-Aviv University Ltd. | Generation of cytotoxic tumor specific cell lines and uses thereof |
US20160017021A1 (en) | 2013-03-06 | 2016-01-21 | Protalix Ltd. | TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME |
WO2014136117A1 (en) | 2013-03-06 | 2014-09-12 | Protalix Ltd. | USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY |
MX364458B (es) | 2013-03-13 | 2019-04-26 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas. |
WO2014164797A2 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
WO2014147622A1 (en) | 2013-03-21 | 2014-09-25 | Collplant Ltd. | Compositions comprising collagen and prp for tissue regeneration |
CA2906314A1 (en) | 2013-03-24 | 2014-10-02 | Biolinerx Ltd. | Methods of treating myeloid leukemia |
RU2015149680A (ru) | 2013-04-21 | 2017-05-24 | Йеда Ресеарч Энд Девелопмент Ко. Лтд. | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w |
ES2831424T3 (es) | 2013-04-23 | 2021-06-08 | Yeda Res & Dev | Células madre pluripotentes naif aisladas y métodos para generarlas |
CN105555796B (zh) | 2013-04-25 | 2019-09-17 | 耶达研究及发展有限公司 | 抑制肽对治疗炎性疾病的用途 |
EP2999717B1 (de) | 2013-05-21 | 2018-08-08 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Behandlung von mastzellen-vermittelten erkrankungen |
EP3626310A1 (de) | 2013-05-27 | 2020-03-25 | Rakuto Bio Technologies Ltd. | Enzymatisches system mit kosmetischen zusammensetzungen |
ES2938044T3 (es) | 2013-06-24 | 2023-04-04 | Univ Ramot | Estructura a base de epiplón y sistema de suministro |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
RU2703498C2 (ru) | 2013-07-19 | 2019-10-17 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с leptinotarsa |
WO2015015489A1 (en) | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
US9938316B2 (en) | 2013-08-29 | 2018-04-10 | Yeda Research And Development Co. Ltd. | Selective inhibitors of α2 isoform of Na,K-ATPase and use thereof for reduction of intra-ocular pressure and as cardiotonic agents |
US20160251410A1 (en) | 2013-09-03 | 2016-09-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
IL228284A (en) | 2013-09-03 | 2016-12-29 | Technion Res & Dev Foundation | Implants from cellular scaffolding and blood vessel stalk |
WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
WO2015037009A1 (en) | 2013-09-16 | 2015-03-19 | Plexicure Ltd. | Isolated proteins capable of binding plexin-a4 and methods of producing and using same |
ES2717446T3 (es) | 2013-09-17 | 2019-06-21 | Yeda Res & Dev | Péptidos derivados de ERK y usos de los mismos |
US20160237404A1 (en) | 2013-10-01 | 2016-08-18 | Kadimastem Ltd. | Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic laterial sclerosis (als) |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
KR20220130254A (ko) | 2013-10-21 | 2022-09-26 | 옵코 바이오로직스 리미티드 | 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법 |
EP3060656A1 (de) | 2013-10-24 | 2016-08-31 | Yeda Research and Development Co., Ltd. | Polynukleotide zur codierung von brex-system-polypeptiden und verfahren zur verwendung davon |
AU2014343214B2 (en) | 2013-10-31 | 2020-04-09 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia with a FLT3 mutation |
AR098295A1 (es) | 2013-11-04 | 2016-05-26 | Monsanto Technology Llc | Composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos |
ES2754207T3 (es) | 2013-11-28 | 2020-04-16 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Inhibidores de la ARN polimerasa I y usos de los mismos |
US10053712B2 (en) | 2013-12-10 | 2018-08-21 | Yeda Research And Development Co. Ltd. | Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-CoA and bacteria expressing same |
UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
CN105979770B (zh) | 2014-01-15 | 2019-07-05 | 孟山都技术公司 | 用于使用epsps多核苷酸的杂草控制的方法和组合物 |
WO2015114633A1 (en) | 2014-01-30 | 2015-08-06 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same |
JP2017506259A (ja) | 2014-02-03 | 2017-03-02 | イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドYissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | 幹細胞を枯渇させるためのカゼインキナーゼi阻害剤の使用 |
CA2936158C (en) | 2014-02-05 | 2023-06-13 | Yeda Research And Development Co. Ltd. | Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease |
US10066014B2 (en) | 2014-02-06 | 2018-09-04 | Yeda Research And Development Co. Ltd. | Anti CD84 antibodies, compositions comprising same and uses thereof |
US20170101633A1 (en) | 2014-02-10 | 2017-04-13 | Protalix Ltd. | Method of maintaining disease stability in a subject having gaucher's disease |
US10564149B2 (en) | 2014-02-11 | 2020-02-18 | Brainstorm Cell Therapeutics Ltd. | Populations of mesenchymal stem cells that secrete neurotrophic factors |
CN106255882A (zh) | 2014-03-03 | 2016-12-21 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 用于检测铜绿假单胞菌的方法和装置 |
EP2923709A1 (de) | 2014-03-28 | 2015-09-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Mehrstufiger Mehrkomponenten-Malariaimpfstoff |
CN110506752B (zh) | 2014-04-01 | 2022-02-18 | 孟山都技术公司 | 用于控制虫害的组合物和方法 |
US11433163B2 (en) | 2014-04-10 | 2022-09-06 | Bonus Therapeutics Ltd. | Bone repair compositions |
EP3132055A2 (de) | 2014-04-14 | 2017-02-22 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Verfahren und kit zur bestimmung des gewebe- oder zellursprungs von dna |
ES2764504T3 (es) | 2014-04-17 | 2020-06-03 | Yeda Res & Dev | Métodos y equipos para analizar restos de unión al ADN fijados al ADN |
SG11201608772UA (en) | 2014-04-27 | 2016-11-29 | Ccam Biotherapeutics Ltd | Humanized antibodies against ceacam1 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
CN106460048B (zh) | 2014-04-28 | 2021-01-05 | 耶达研究及发展有限公司 | 针对试剂的微生物组应答 |
BR112016024555A2 (pt) | 2014-05-04 | 2018-01-23 | Forrest Innovations Ltd | composições e métodos de utilização das mesmas para reduzir a resistência contra larvicidas para mosquitos |
EP3145947A2 (de) | 2014-05-22 | 2017-03-29 | Yeda Research and Development Co., Ltd. | Rekombinante mikroorganismen zur kohlenstofffixierung |
EP3149155B1 (de) | 2014-06-02 | 2020-09-23 | Kadimastem Ltd. | Verfahren zur induzierung der myelinisierung und reifung von oligodendrozyten |
WO2015186129A1 (en) | 2014-06-02 | 2015-12-10 | Technion Research & Development Foundation Limited. | Compositions and methods of selectively inhibiting irp1 and treating inflammation |
WO2015200223A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
EP3145951A1 (de) | 2014-06-24 | 2017-03-29 | InSight Biopharmaceuticals Ltd. | Verfahren zur reinigung von antikörpern |
WO2015198334A2 (en) | 2014-06-25 | 2015-12-30 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Identification of cancer stem cells and use of same for diagnosis and treatment |
US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
WO2015198326A1 (en) | 2014-06-26 | 2015-12-30 | Ramot At Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
WO2016009436A1 (en) | 2014-07-15 | 2016-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Isolated polypeptides of cd44 and uses thereof |
JP6700249B2 (ja) | 2014-07-21 | 2020-06-10 | ノベルラスディクス リミテッド | 患者特有の変異の薬物応答を測定する方法 |
CA2955414A1 (en) | 2014-07-21 | 2016-01-28 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
UA125244C2 (uk) | 2014-07-29 | 2022-02-09 | Монсанто Текнолоджі Елелсі | Спосіб умертвіння або припинення росту комахи |
JP2017525351A (ja) | 2014-07-30 | 2017-09-07 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 多能性幹細胞の培養用培地 |
CN111624346A (zh) | 2014-08-14 | 2020-09-04 | 米密德诊断学有限公司 | 用于预测及/或决定预后的套组 |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | チロシンキナーゼ阻害薬(tki)に耐性のがんを処置するための組成物および方法 |
CA2959716A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
EP2992895A1 (de) | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Mehrstufiger Dreikomponenten-Malariaimpfstoff |
IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
US10174320B2 (en) | 2014-09-21 | 2019-01-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Downregulating miR-132 for the treatment of lipid related disorders |
EP3739062B1 (de) | 2014-10-20 | 2023-08-16 | Gen-Probe Incorporated | Lyselösung roter blutkörperchen |
US10570368B2 (en) | 2014-11-13 | 2020-02-25 | Enzootic Holdings Ltd. | Functional sex-reversal of decapod crustacean females |
CA2967233A1 (en) | 2014-11-17 | 2016-05-26 | Yeda Research And Development Co. Ltd. | Method of analyzing microbiome |
US20180042994A1 (en) | 2014-11-17 | 2018-02-15 | Yeda Research And Development Co. Ltd. | Methods of treating diseases related to mitochondrial function |
BR112017010555A2 (pt) | 2014-11-20 | 2018-02-27 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | composições e métodos para produção de polipeptídeos com padrão de glicosilação modificado em células vegetais |
JP6860483B2 (ja) | 2014-11-26 | 2021-04-14 | テクノロジー イノベーション モメンタム ファンド(イスラエル)リミテッド パートナーシップTechnology Innovation Momentum Fund(israel)Limited Partnership | 細菌遺伝子の標的化削減 |
US10883111B2 (en) | 2014-11-27 | 2021-01-05 | Danziger Innovations Ltd. | Nucleic acid constructs for genome editing |
WO2016092555A2 (en) | 2014-12-11 | 2016-06-16 | Yeda Research And Development Co. Ltd. | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
AU2015373050B2 (en) | 2014-12-30 | 2022-09-29 | Cell Cure Neurosciences Ltd. | RPE cell populations and methods of generating same |
CA2972580A1 (en) | 2014-12-30 | 2016-07-07 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
EA201791518A1 (ru) | 2014-12-30 | 2017-10-31 | Селл Кьюр Нейросайансес Лтд. | Способы лечения заболеваний сетчатки |
RU2017125957A (ru) | 2015-01-04 | 2019-02-04 | Проталикс Лтд. | Модифицированная днказа и ее применения |
WO2016116935A1 (en) | 2015-01-21 | 2016-07-28 | Yeda Research And Development Co. Ltd. | Use of rasa2 as a prognostic and therapeutic marker for melanoma |
US10968449B2 (en) | 2015-01-22 | 2021-04-06 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
WO2016135732A1 (en) | 2015-02-26 | 2016-09-01 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
EP3268475B1 (de) | 2015-03-11 | 2020-10-21 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Köderoligonukleotide zur behandlung von krankheiten |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
US20180064748A1 (en) | 2015-03-27 | 2018-03-08 | Yeda Research And Development Co. Ltd. | Methods of treating motor neuron diseases |
US11136401B2 (en) | 2015-03-27 | 2021-10-05 | University Of Southern California | Car t-cell therapy directed to LHR for the treatment of solid tumors |
KR20170132293A (ko) | 2015-03-31 | 2017-12-01 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 글루타메이트 옥살로아세테이트 트랜스아미나제 1(got1) 제제와 이의 제조방법 및 용도 |
US10960035B2 (en) | 2015-04-01 | 2021-03-30 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) | Erodium crassifolium L'Her plant extracts and uses thereof |
DK3280401T3 (da) | 2015-04-07 | 2021-11-15 | Ela Pharma Ltd | Sammensætninger til behandling og/eller forebyggelse af celle- eller vævsnekrose specielt rettet mod kathepsin c og/eller cela1 og/eller cela3a og/eller strukturelt relaterede enzymer dertil |
EP3081575A1 (de) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium-parasiten-antikörper |
WO2016174674A1 (en) | 2015-04-27 | 2016-11-03 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions |
BR112017023448A2 (pt) | 2015-04-29 | 2018-07-31 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | composições anti-fitopatogênicas |
US20190031759A1 (en) | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
EP3292219B9 (de) | 2015-05-04 | 2022-05-18 | Ramot at Tel-Aviv University Ltd. | Verfahren und kits zur fragmentierung von dna |
WO2016181393A1 (en) | 2015-05-11 | 2016-11-17 | Yeda Research And Development Co. Ltd. | Citrin inhibitors for the treatment of cancer |
WO2016185471A1 (en) | 2015-05-17 | 2016-11-24 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Compositions and methods for treating cancer |
WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
US10849985B2 (en) | 2015-05-20 | 2020-12-01 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
WO2016185469A1 (en) | 2015-05-21 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Bacterial populations for promoting health |
EP3302571B1 (de) | 2015-05-29 | 2020-11-18 | OPKO Biologics Ltd. | Pegylierte oxyntomodulin-varianten |
UY36703A (es) | 2015-06-02 | 2016-12-30 | Monsanto Technology Llc | Composiciones y métodos para la administración de un polinucleótido en una planta |
WO2016196782A1 (en) | 2015-06-03 | 2016-12-08 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
EP3302559B1 (de) | 2015-06-04 | 2022-01-12 | University of Southern California | Auf lym-1 und lym-2 abgerichtete car-zellen-immuntherapie |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
WO2016203476A1 (en) | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
ES2917884T3 (es) | 2015-06-18 | 2022-07-12 | Yeda Res & Dev | Protocolos de acondicionamiento y uso de los mismos para la regeneración de tejidos |
ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
WO2017009843A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
AU2016291825B2 (en) | 2015-07-16 | 2022-08-11 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory T cells and use of same in immunotherapy |
EP3325494B1 (de) | 2015-07-19 | 2020-12-30 | Yeda Research and Development Co., Ltd. | Selektive inhibitoren der alpha2-haltigen isoformen der na, k-atpase und deren verwendung zur reduzierung des augeninnendruckes |
WO2017013661A1 (en) | 2015-07-22 | 2017-01-26 | Phytopharma International Ltd. | Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby |
US11230696B2 (en) | 2015-07-29 | 2022-01-25 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
EP3331546B1 (de) | 2015-08-03 | 2023-10-04 | Biokine Therapeutics Ltd. | Cxcr4-antagonist zur behandlung von krebs |
WO2017021961A1 (en) | 2015-08-04 | 2017-02-09 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
EA201890424A1 (ru) | 2015-08-05 | 2018-06-29 | Селл Кьюр Нейросайансес Лтд. | Получение клеток пигментного эпителия сетчатки |
EA201890442A1 (ru) | 2015-08-05 | 2018-07-31 | Селл Кьюр Нейросайансес Лтд. | Получение фоторецепторов для лечения заболеваний сетчатки |
EP3334449B1 (de) | 2015-08-10 | 2021-09-29 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Verfahren und pharmazeutische zusammensetzungen zur verbesserung der wundheilung mithilfe von cd24 |
US20180237790A1 (en) | 2015-08-13 | 2018-08-23 | Forrest Innovation Ltd. | Formulations and compositions for delivery of nucleic acids to plant cells |
WO2017033188A1 (en) | 2015-08-24 | 2017-03-02 | Yeda Research And Development Co. Ltd. | Algal oil and biofuel and methods of producing same |
US10765706B2 (en) | 2015-09-03 | 2020-09-08 | University Of South Florida | Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers |
WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
WO2017072757A1 (en) | 2015-10-25 | 2017-05-04 | Yeda Research And Development Co. Ltd. | Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same |
WO2017072763A1 (en) | 2015-10-26 | 2017-05-04 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
CA3002767C (en) | 2015-10-27 | 2023-03-14 | Zvi VOGEL | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method for inducing the division of cardiomyocytes and treating heart diseases |
EP3370791A1 (de) | 2015-11-03 | 2018-09-12 | Ariel-University Research and Development Company Ltd. | Zusammensetzungen zur regeneration und reparatur von nervengewebe |
WO2017081689A1 (en) | 2015-11-11 | 2017-05-18 | Ramot At Tel-Aviv University Ltd. | Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer |
WO2017094001A1 (en) | 2015-11-30 | 2017-06-08 | Kadimastem Ltd | Methods for differentiating and purifying pancreatic endocrine cells |
US10228367B2 (en) | 2015-12-01 | 2019-03-12 | ProteinSimple | Segmented multi-use automated assay cartridge |
EP3176183A1 (de) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Zusammensetzungen und verfahren zur behandlung von krebs ohne resistenz gegen einen tyrosinkinasehemmer (tki) |
WO2017103930A1 (en) | 2015-12-16 | 2017-06-22 | Ramot At Tel-Aviv University Ltd. | Particles comprising decellularized omentum |
WO2017115367A1 (en) | 2015-12-28 | 2017-07-06 | The National Institute for Biotechnology in the Negev Ltd. | Composition and method for treating amyotrophic lateral sclerosis |
EP3400068A1 (de) | 2016-01-06 | 2018-11-14 | Yeda Research and Development Co., Ltd. | Zusammensetzungen und verfahren zur behandlung von bösartigen, autoimmun- und entzündungserkrankungen |
EP3403091B1 (de) | 2016-01-11 | 2021-12-22 | Technion Research & Development Foundation Limited | Verfahren zur bestimmung der prognose von sepsis und behandlung davon |
BR112018014902A2 (pt) | 2016-01-21 | 2018-12-18 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | plantas partenocárpicas do tipo solanácea, frutos e sementes de uma planta, produtos processados comestíveis, métodos de produção e de reprodução de uma planta, |
IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive wires |
IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | The composition containing sp1 protein and carbon nanoparticles and its uses |
EP3408376A1 (de) | 2016-01-31 | 2018-12-05 | Hadasit Medical Research Services and Development Ltd. | Autosomale-identische pluripotente stammzellpopulationen mit nicht identischer geschlechtschromosomenzusammensetzung und verwendungen davon |
JP7072508B2 (ja) | 2016-02-04 | 2022-05-20 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 変異型p53と関連している疾患、障害または病状の処置におけるペプチドおよびその使用 |
EP3414346B1 (de) | 2016-02-14 | 2019-11-13 | Yeda Research and Development Co. Ltd. | Mikrobiombasierte diagnose, vorhersage und behandlung von rezidivierender fettleibigkeit |
US20190046497A1 (en) | 2016-02-14 | 2019-02-14 | Yeda Research And Development Co., Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
JP2019508422A (ja) | 2016-02-16 | 2019-03-28 | イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドYissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | シアノバクテリアおよび植物の増殖を阻害するための非タンパク質性フェニルアラニン類似体 |
EP3420075A4 (de) | 2016-02-23 | 2019-10-16 | Chaya Brodie | Erzeugung von krebsstammzellen und verwendung davon |
RU2756275C2 (ru) | 2016-03-01 | 2021-09-29 | Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. | Антитела, специфические к рецептору полиовируса (pvr) человека |
CN108699609A (zh) | 2016-03-03 | 2018-10-23 | 米密德诊断学有限公司 | 分析rna用于诊断感染类型 |
US20190216891A1 (en) | 2016-03-06 | 2019-07-18 | Yeda Research And Development Co., Ltd. | Method for modulating myelination |
IL244649A0 (en) | 2016-03-17 | 2016-06-30 | Yeda Res & Dev | Methods for the isolation of barrel-like proteases and the identification of peptides that are cleaved by Alidan |
US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
EP3736332A1 (de) | 2016-04-27 | 2020-11-11 | Gen-Probe Incorporated | Reagens für blutzellenlyse |
EP3463402B1 (de) | 2016-05-22 | 2021-06-23 | Yeda Research and Development Co. Ltd. | Verfahren zur verwendung von lungenzellen zur transplantation und induktion von toleranz |
IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
WO2017208247A1 (en) | 2016-06-02 | 2017-12-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
EP3464322B1 (de) | 2016-06-05 | 2023-04-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Neuartige moleküle zur behandlung von entzündungen |
WO2017212494A1 (en) | 2016-06-09 | 2017-12-14 | Opko Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
US11859232B2 (en) | 2016-06-19 | 2024-01-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Screening for chemotherapy resistance in human haploid cells |
US10961504B2 (en) | 2016-06-27 | 2021-03-30 | Yeda Research And Development Co. Ltd. | Veto cells generated from memory T cells |
CN109661578B (zh) | 2016-07-10 | 2022-05-10 | 米密德诊断学有限公司 | 用于区分细菌和病毒感染的蛋白质特征 |
EP3482201B1 (de) | 2016-07-10 | 2022-12-14 | Memed Diagnostics Ltd. | Frühe diagnose von infektionen |
PT3481855T (pt) | 2016-07-11 | 2023-11-27 | Opko Biologics Ltd | Fator vii de coagulação de ação prolongada e métodos de produção do mesmo |
JP7268943B2 (ja) | 2016-07-11 | 2023-05-08 | ボーナス セラピューティックス リミテッド | 組織再生のための細胞組成物 |
IL246722A0 (en) | 2016-07-11 | 2016-09-29 | Yeda Res & Dev | Combined treatment to increase endogenous synthesis of nitric oxide |
US20200080050A1 (en) | 2016-07-11 | 2020-03-12 | Yaakov Nahmias | Systems and methods for growing cells in vitro |
WO2018015881A1 (en) | 2016-07-18 | 2018-01-25 | Ramot At Tel-Aviv University Ltd. | Modular platform for targeted therapeutics |
US20190203270A1 (en) | 2016-07-24 | 2019-07-04 | Yeda Research And Development Co., Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
EP3497231B1 (de) | 2016-08-08 | 2023-10-04 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bakterielle systeme zur analyse von ubiquitinierten polypeptiden |
US20190180846A1 (en) | 2016-08-10 | 2019-06-13 | Memed Diagnostics Ltd. | System and method for analysis of biological data |
US10633706B2 (en) | 2016-08-10 | 2020-04-28 | Ramot At Tel-Aviv University Ltd. | Analysis of methylation status and copy number |
SG11201901272WA (en) | 2016-08-14 | 2019-03-28 | Univ Ramot | Mesenchymal cell-derived exosomes to treat neurological disorders |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
WO2018047154A1 (en) | 2016-09-07 | 2018-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
EP3512943B1 (de) | 2016-09-14 | 2023-04-12 | Yeda Research and Development Co. Ltd. | Crisp-seq, integriertes verfahren für massiv parallele einzelzellen-rna-seq und crispr-gepoolte screens |
WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
IL248468A0 (en) | 2016-10-13 | 2017-01-31 | Technion Res & Dev Foundation | Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing |
IL248385A0 (en) | 2016-10-18 | 2017-02-01 | Yeda Res & Dev | Treatment of circadian rhythm disorder |
WO2018087759A1 (en) | 2016-11-10 | 2018-05-17 | Yeda Research And Development Co. Ltd. | Phosphotriesterases for treating or preventing organophosphate exposure associated damage |
US11542508B2 (en) | 2016-11-28 | 2023-01-03 | Yeda Research And Development Co. Ltd. | Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest |
US20190343782A1 (en) | 2016-11-30 | 2019-11-14 | Yeda Research And Development Co. Ltd. | Methods of treating liver toxicity and disorders |
MX2018016003A (es) | 2016-12-01 | 2019-05-16 | Univ Ramot | Tratamiento combinado para lesiones neurológicas. |
US11555178B2 (en) | 2017-01-18 | 2023-01-17 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production |
IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
EP3596469A1 (de) | 2017-03-12 | 2020-01-22 | Yeda Research and Development Co., Ltd. | Verfahren zur diagnose und prognose von krebs |
WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
KR20200031559A (ko) | 2017-03-16 | 2020-03-24 | 리니지 셀 테라퓨틱스, 인크. | 망막 질환 요법의 치료 효과를 측정하는 방법 |
EP4317971A3 (de) | 2017-04-05 | 2024-04-17 | Yeda Research and Development Co. Ltd | Ex-vivo-kultursystem und verfahren zur verwendung davon |
IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
JP7445429B2 (ja) | 2017-05-10 | 2024-03-07 | アリエル サイエンティフィック イノベーションズ リミテッド | 抗体の精製法 |
EP3652541B1 (de) | 2017-05-21 | 2022-12-14 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Kombination von markern zur diagnose von krebs |
US20200172604A1 (en) | 2017-05-23 | 2020-06-04 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
EP3630973A1 (de) | 2017-05-31 | 2020-04-08 | Tropic Biosciences UK Limited | Verfahren zur auswahl von zellen mit genomeditierungsereignissen |
GB201708662D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing shelf-life of banana |
GB201708665D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
EP3652342A1 (de) | 2017-07-13 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Erkennung gewebespezifischer dna |
EP3652343A1 (de) | 2017-07-13 | 2020-05-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Digitale tröpfchen-pcr-strategie mit zwei sonden zur spezifischen detektion gewebespezifischer zirkulierender dna-moleküle |
EP4403646A2 (de) | 2017-07-13 | 2024-07-24 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Dna-ziele als gewebespezifische methylierungsmarker |
IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
US11692166B2 (en) | 2017-08-23 | 2023-07-04 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
WO2019058253A1 (en) | 2017-09-19 | 2019-03-28 | Tropic Biosciences UK Limited | MODIFICATION OF THE SPECIFICITY OF NON-CODING RNA MOLECULES FOR SILENCING GENE EXPRESSION IN EUKARYOTIC CELLS |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
CA3083436A1 (en) | 2017-11-29 | 2019-06-06 | Weedout Ltd. | Compositions, kits and methods for controlling weed of the amaranthus genus |
EP3717032B1 (de) | 2017-11-29 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Verfahren zur vorbeugung oder behandlung von neurogenem schock |
WO2019106680A1 (en) | 2017-12-03 | 2019-06-06 | Yeda Research And Development Co. Ltd. | Treatment of an ischemic heart disease |
EP3723785A1 (de) | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Komplexe modulatoren des cop9-signalosoms (csn) und deren verwendung |
EP3731965A1 (de) | 2017-12-28 | 2020-11-04 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Verfahren zur wiedergabe von biorhythmen auf einem mikrofluidischen chip |
IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
IL257269A (en) | 2018-01-31 | 2018-04-09 | Olender Tsviya | Signaling is directed to the endoplasmic reticulum |
EP3749689A1 (de) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Inhibitoren des 20s-proteasoms |
WO2019155465A1 (en) | 2018-02-08 | 2019-08-15 | Yeda Research And Development Co. Ltd. | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
EP3755340A4 (de) | 2018-02-23 | 2021-11-17 | Carmel-Haifa University Economic Corporation Ltd. | Verfahren zur behandlung von gedächtnisstörungen und kognitiver dysfunktion |
EP3759493A1 (de) | 2018-02-28 | 2021-01-06 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Verfahren zur diagnose und behandlung von blasenkrebs |
EP3765034A1 (de) | 2018-03-12 | 2021-01-20 | Yeda Research and Development Co. Ltd | Behandlung einer herzkrankheit |
IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
EP3774047A1 (de) | 2018-03-29 | 2021-02-17 | Yeda Research and Development Co. Ltd | Verwendung von elektrischen feldgradienten zur kontrolle der genexpression |
JP7518498B2 (ja) | 2018-03-29 | 2024-07-18 | テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド | Pten阻害剤を含む小胞およびその使用 |
GB201807192D0 (en) | 2018-05-01 | 2018-06-13 | Tropic Biosciences Uk Ltd | Compositions and methods for reducing caffeine content in coffee beans |
WO2019220441A1 (en) | 2018-05-15 | 2019-11-21 | Hadasit Medical Research Services And Development Ltd. | Compositions and methods for treating cancer resistant to an anti-cancer agent |
IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neo-antigens |
AU2019277908A1 (en) | 2018-05-27 | 2021-01-07 | Biolinerx Ltd. | AGI-134 combined with a checkpoint inhibitor for the treatment of solid tumors |
WO2019234754A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Nucleic acid constructs and methods of using same |
WO2019234750A1 (en) | 2018-06-07 | 2019-12-12 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of regenerating and transforming cannabis |
EP3810636A1 (de) | 2018-06-25 | 2021-04-28 | Yeda Research and Development Co. Ltd | Systeme und verfahren zur erhöhung der effizienz von genomeditierung |
EP3818075A1 (de) | 2018-07-04 | 2021-05-12 | Ukko Inc. | Verfahren zum de-epitoping von weizenproteinen und verwendung davon zur behandlung von zöliakie |
US20210269860A1 (en) | 2018-07-08 | 2021-09-02 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
CA3100961A1 (en) | 2018-07-11 | 2020-01-16 | Immunity Pharma Ltd. | Peptide compounds and therapeutic uses of same |
BR112021000360A2 (pt) | 2018-07-11 | 2021-04-13 | Kahr Medical Ltd. | Proteína de fusão variante sirpalpha-4-1bbl e métodos de uso da mesma |
EP3827087A1 (de) | 2018-07-31 | 2021-06-02 | CollPlant Ltd. | Transgenes tabakereignis und verfahren zur detektion und verwendung davon |
IL261156A (en) | 2018-08-14 | 2020-02-27 | Fass Deborah | Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same |
JP2021535100A (ja) | 2018-08-24 | 2021-12-16 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | M2マクロファージ極性化を調節する方法及び治療におけるその使用 |
CA3112135A1 (en) | 2018-09-20 | 2020-03-26 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral sclerosis |
US20210338767A1 (en) | 2018-09-25 | 2021-11-04 | Biolinerx Ltd. | Methods of selecting treatment for cxcr4-associated cancer |
IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
EP3914698A1 (de) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Kulturmedien für pluripotente stammzellen |
IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use |
IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
EP3927378A1 (de) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Verfahren zur reduktion von arzneimittelinduzierter nephrotoxizität |
WO2020170239A1 (en) | 2019-02-21 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of generating organoids for high throughput screening of drugs |
CN113692225B (zh) | 2019-03-05 | 2023-04-18 | 以色列农业和农村发展部农业研究组织(范卡尼中心) | 经基因组编辑的鸟类 |
GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Bistable type ii opsins and uses thereof |
WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
EP3946611A2 (de) | 2019-03-31 | 2022-02-09 | Yeda Research and Development Co. Ltd | Antivirale und antitumorale verbindungen |
IL266433B (en) | 2019-05-02 | 2020-11-30 | Sagi Irit | Compositions comprising the propeptide of lysyl oxidase and uses thereof |
US20220220559A1 (en) | 2019-05-13 | 2022-07-14 | Yeda Research And Development Co. Ltd. | Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases |
IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
JP2022533745A (ja) | 2019-05-22 | 2022-07-25 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | ヒト多能性細胞を培養する方法 |
CA3140406A1 (en) | 2019-05-28 | 2020-12-03 | Shanghaitech University | Composition and methods to treat ectodermal dysplasia 2, clouston type |
CA3141995A1 (en) | 2019-06-12 | 2020-12-17 | Hadasit Medical Research Services And Development Ltd. | Methods of generating oligodendrocytes |
US20220307008A1 (en) | 2019-06-16 | 2022-09-29 | Yeda Research And Development Co. Ltd. | Method for stabilizing intracellular rna |
WO2020261281A1 (en) | 2019-06-27 | 2020-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
CA3145972A1 (en) | 2019-07-04 | 2021-01-07 | Ukko Inc. | De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity |
US20220267409A1 (en) | 2019-07-11 | 2022-08-25 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
WO2021009740A1 (en) | 2019-07-16 | 2021-01-21 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for the treatment of tuberculosis |
WO2021019526A1 (en) | 2019-07-29 | 2021-02-04 | Yeda Research And Development Co. Ltd. | Methods of treating and diagnosing lung cancer |
US20220298522A1 (en) | 2019-07-30 | 2022-09-22 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
WO2021028909A1 (en) | 2019-08-12 | 2021-02-18 | Yeda Research And Development Co. Ltd. | Dna repair blood test for predicting response of lung cancer patients to immunotherapy |
US20240140988A1 (en) | 2019-08-22 | 2024-05-02 | Ariel Scientific Innovations Ltd. | Scaled-up methods for purifying antibodies |
WO2021038569A1 (en) | 2019-08-27 | 2021-03-04 | Yeda Research And Development Co. Ltd. | Treatment of bacterial vaginosis |
WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
IL269674B (en) | 2019-09-25 | 2020-08-31 | Roy Bar Ziv | Assembling protein complexes on a chip |
IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
WO2021084526A1 (en) | 2019-10-31 | 2021-05-06 | Yeda Research And Development Co. Ltd. | Engineered autotrophic bacteria for co2 conversion to organic materials |
CA3160506A1 (en) | 2019-11-11 | 2021-05-20 | Ibi-Ag Innovative Bio Insecticides Ltd. | Insect control nanobodies and uses thereof |
US20230022576A1 (en) | 2019-11-19 | 2023-01-26 | Protalix Ltd. | Removal of constructs from transformed cells |
IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
EP4077731A1 (de) | 2019-12-22 | 2022-10-26 | Yeda Research and Development Co. Ltd | Diagnose einer frontotemporalen demenz |
IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | System and methods for identifying cells that have undergone genome editing |
US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
IL271778A (en) | 2019-12-31 | 2021-06-30 | Ichilov Tech Ltd | Methods for treating atopic dermatitis |
IL272074B1 (en) | 2020-01-15 | 2024-08-01 | Immunity Pharma Ltd | Peptide compounds and their use in methods of treating diseases |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multi-target antibodies for use in the treatment of diseases |
WO2021152584A1 (en) | 2020-01-28 | 2021-08-05 | Ariel Scientific Innovations Ltd. | Methods of analyzing cell membranes |
EP4096647A1 (de) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Behandlung einer akuten lebererkrankung mit tlr-mik-inhibitoren |
WO2021152586A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
IL295500A (en) | 2020-02-09 | 2022-10-01 | Nlc Pharma Ltd | Rapid detection test for sars-cov-2 |
IL272586A (en) | 2020-02-10 | 2021-08-31 | Yeda Res & Dev | A method for cell cluster analysis |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
US20230127559A1 (en) | 2020-03-16 | 2023-04-27 | Yeda Research And Development Co. Ltd. | Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein |
BR112022019510A2 (pt) | 2020-03-29 | 2022-11-16 | Yeda Res & Dev | Variantes de beta-glucocerebrosidase para uso no tratamento de doença de gaucher |
EP4125440A1 (de) | 2020-03-31 | 2023-02-08 | Biomuse Ltd. | Bakterien zur vorbeugung und behandlung von rauchinduzierten lungenschäden |
WO2021205444A1 (en) | 2020-04-06 | 2021-10-14 | Yeda Research And Development Co. Ltd. | Methods of diagnosing cancer and predicting responsiveness to therapy |
EP4132479A1 (de) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiolhaltige zusammensetzungen und verwendungen davon |
US20230135456A1 (en) | 2020-04-13 | 2023-05-04 | Exoprother Medical Ltd. | Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
WO2021229577A1 (en) | 2020-05-12 | 2021-11-18 | Collplant Ltd. | Collagen as a delivery tool for metal-based anti-viral agents |
IL274811B (en) | 2020-05-20 | 2021-05-31 | Yeda Res & Dev | Spatial information is developed for the analysis of individual cells |
US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
US20230309480A1 (en) | 2020-08-18 | 2023-10-05 | International Rice Research Institute | Methods of increasing outcrossing rates in gramineae |
IL277488A (en) | 2020-09-21 | 2022-04-01 | Yeda Res & Dev | Weight regulation method |
WO2022064494A2 (en) | 2020-09-23 | 2022-03-31 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating coronaviral infections |
IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | A method for diagnosing breast cancer |
WO2022074646A1 (en) | 2020-10-05 | 2022-04-14 | Protalix Ltd. | Dicer-like knock-out plant cells |
WO2022074656A1 (en) | 2020-10-07 | 2022-04-14 | Protalix Ltd. | Long-acting dnase |
EP4228637A1 (de) | 2020-10-15 | 2023-08-23 | Yeda Research and Development Co. Ltd | Verfahren zur behandlung von myeloidmalignitäten |
IL278401A (en) | 2020-10-29 | 2022-05-01 | Yeda Res & Dev | Polynucleotides for editing RNA and a method for using them |
IL302594A (en) | 2020-11-09 | 2023-07-01 | 1E Therapeutics Ltd | Methods based on catalytic sequences for the treatment or prevention of bacterial infections |
EP4251641A1 (de) | 2020-11-26 | 2023-10-04 | Ukko Inc. | Modifizierte gluteninuntereinheit mit hohem molekulargewicht und verwendungen davon |
IL279559A (en) | 2020-12-17 | 2022-07-01 | Yeda Res & Dev | Controlling the ubiquitination process of mlkl for disease treatment |
WO2022144882A2 (en) | 2020-12-28 | 2022-07-07 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
KR20230133859A (ko) | 2020-12-28 | 2023-09-19 | 1이 테라퓨틱스 엘티디. | p21 mRNA 표적화 DNA자임 |
JP2024502377A (ja) | 2021-01-10 | 2024-01-18 | スーパーミート ザ エッセンス オブ ミート リミテッド | 培養肉産業用の多能性幹細胞凝集体及びそれから得られる微小組織 |
WO2022153286A1 (en) | 2021-01-14 | 2022-07-21 | Yeda Research And Development Co. Ltd. | Methods of producing vitamin d |
IL280340B (en) | 2021-01-21 | 2022-04-01 | Yeda Res & Dev | Antibodies, peptides and their combinations for the treatment and prevention of corona virus infections |
EP4294429A1 (de) | 2021-02-18 | 2023-12-27 | Yeda Research and Development Co. Ltd | Genetisch modifizierte bakterien zur erzeugung von impfstoffen |
JP2024506955A (ja) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ワクチンを作製する方法 |
IL281561A (en) | 2021-03-16 | 2022-10-01 | Yeda Res & Dev | Methods and devices for growing mouse embryos outside the uterus |
CA3213424A1 (en) | 2021-03-30 | 2022-10-06 | Lior Moshe ZELCBUCH | Pseudomonas bacteriophage and uses thereof |
IL282188A (en) | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | Combined use of ketamine and bretigabine for the treatment of psychiatric disorders |
AU2022272135A1 (en) | 2021-05-12 | 2024-01-04 | Biomx Ltd. | Staphylococcus bacteriophage and uses thereof |
IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases |
IL309061A (en) | 2021-06-06 | 2024-02-01 | Yeda res & development co ltd | Combined cancer treatment |
CN117836402A (zh) | 2021-06-13 | 2024-04-05 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 重编程人细胞的方法 |
NL2028466B1 (en) | 2021-06-16 | 2022-12-21 | Sakata Holland B V | Methods of sorting matthiola seeds |
WO2022264076A1 (en) | 2021-06-16 | 2022-12-22 | Seedx Technologies Inc. | Methods of sorting matthiola seeds |
CA3223344A1 (en) | 2021-07-02 | 2023-01-05 | Tropic Biosciences UK Limited | Delay or prevention of browning in banana fruit |
WO2023003809A1 (en) | 2021-07-18 | 2023-01-26 | Gamida-Cell Ltd. | Therapeutic nk cell populations |
WO2023002492A1 (en) | 2021-07-22 | 2023-01-26 | Yeda Research And Development Co. Ltd. | Codon optimization of nucleic acids |
EP4130028A1 (de) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Manipulierter tcr-komplex und verfahren zur verwendung davon |
KR20240040770A (ko) | 2021-08-03 | 2024-03-28 | 제니시티 리미티드 | 조작된 tcr 복합체 및 이의 사용 방법 |
EP4384603A1 (de) | 2021-08-10 | 2024-06-19 | Gamida-Cell Ltd. | Manipulierte nk-zellen, verfahren zu deren herstellung und verwendungen davon |
GB202112866D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to fusarium wilt in a banana |
GB202112865D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to black sigatoka disease in banana |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
AU2022404031A1 (en) | 2021-12-08 | 2024-07-25 | Board Of Regents, The University Of Texas System | Multipotent lung progenitor cells for lung regeneration |
WO2023209708A1 (en) | 2022-04-25 | 2023-11-02 | Yeda Research And Development Co. Ltd. | Compositions for altering cyclic adp-ribose secondary messenger signalling |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3592888A (en) * | 1968-01-19 | 1971-07-13 | Mount Sinai Hospital Research | Radioimmunoassay of angiotensin and renin activity |
US3646346A (en) * | 1968-12-26 | 1972-02-29 | Pharmacia Ab | Antibody-coated tube system for radioimmunoassay |
-
1971
- 1971-12-21 US US210510A patent/US3867517A/en not_active Expired - Lifetime
-
1972
- 1972-12-12 CA CA158,644A patent/CA988420A/en not_active Expired
- 1972-12-13 ZA ZA728798A patent/ZA728798B/xx unknown
- 1972-12-18 AU AU50214/72A patent/AU470050B2/en not_active Expired
- 1972-12-18 PH PH14185A patent/PH13655A/en unknown
- 1972-12-19 GB GB5866272A patent/GB1414480A/en not_active Expired
- 1972-12-19 FR FR7245321A patent/FR2164705B1/fr not_active Expired
- 1972-12-20 CH CH1856372A patent/CH568061A5/xx not_active IP Right Cessation
- 1972-12-20 DE DE19722262413 patent/DE2262413B2/de not_active Ceased
- 1972-12-20 NL NL7217371A patent/NL7217371A/xx active Search and Examination
- 1972-12-20 BE BE793061A patent/BE793061A/xx unknown
- 1972-12-20 CH CH1026375A patent/CH589445A5/xx not_active IP Right Cessation
- 1972-12-20 AT AT1088772A patent/AT326818B/de not_active IP Right Cessation
- 1972-12-20 IT IT54886/72A patent/IT988084B/it active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0019504A1 (de) * | 1979-04-20 | 1980-11-26 | Merck & Co. Inc. | RIA für Hepatitis-A-Antigen und Antigen-Antikörper-Radionuclid dafür |
Also Published As
Publication number | Publication date |
---|---|
GB1414480A (en) | 1975-11-19 |
FR2164705A1 (de) | 1973-08-03 |
CH589445A5 (de) | 1977-07-15 |
AU470050B2 (en) | 1974-06-20 |
ZA728798B (en) | 1974-02-27 |
AU5021472A (en) | 1974-06-20 |
NL7217371A (de) | 1973-06-25 |
CH568061A5 (de) | 1975-10-31 |
FR2164705B1 (de) | 1976-10-29 |
BE793061A (fr) | 1973-06-20 |
US3867517A (en) | 1975-02-18 |
PH13655A (en) | 1980-08-21 |
ATA1088772A (de) | 1975-03-15 |
AT326818B (de) | 1975-12-29 |
IT988084B (it) | 1975-04-10 |
CA988420A (en) | 1976-05-04 |
DE2262413B2 (de) | 1977-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2262413A1 (de) | Direkte radioimmunpruefung auf antigene und ihre antikoerper | |
DE2450523C3 (de) | Verfahren zum immunologischen Nachweis von Proteinen | |
DE2734118A1 (de) | Radioimmunologisches verfahren und einrichtung zur bestimmung von antigenen | |
Schams et al. | Radioimmunologische LH-Bestimmung im Blutserum vom Rind unter besonderer Berücksichtigung des Brunstzyklus | |
DE2936307C2 (de) | ||
DE2262479A1 (de) | Testvorrichtung fuer eine direkte radioimmunpruefung auf antigene oder deren antikoerper | |
DE2600465C3 (de) | Verfahren zur radioimmunologischen Bestimmung von Östrogenen | |
DE2461811A1 (de) | Immunologisches bestimmungsverfahren | |
EP0257352B1 (de) | Verfahren und Testkit zur Bestimmung freier Wirkstoffe in biologischen Flüssigkeiten | |
DE2602068C2 (de) | Reagens zur Unlöslichmachung eines Antigen/Antikörper-Komplexes | |
DE2651139A1 (de) | Reagens zur durchfuehrung eines direktagglutinationstests zum schwangerschaftsnachweis und verfahren zu seiner herstellung | |
DE2539242A1 (de) | Radioimmunologisches analyseverfahren zur bestimmung von digoxin | |
DE2615092A1 (de) | Verfahren zur quantitativen bestimmung von antigenen substanzen und testpackung zur durchfuehrung des verfahrens | |
DE3633497A1 (de) | Immunometrisches bestimmungsverfahren | |
DE2531176B2 (de) | Verfahren zum Nachweis von Gonorrhoe-Antikörpern | |
DE2816830A1 (de) | Antikoerper-doppelbeschichtetes testroehrchen und seine verwendung im radioimmunassay | |
DE68907365T2 (de) | Verfahren zur Bestimmung des Vorhandenseins leichter Ketten in Urinproben, Komplex von Vorbereitungen zur Erledigung des Verfahrens und damit verbundenes Reagenz. | |
EP0809805B2 (de) | Verwendung von polyklonalen humanen anti-htg-autoantikörpern als reagenz für die klinische diagnostik von schilddrüsen-autoimmunerkrankungen sowie reagenziensatz für eine bestimmung von anti-htg-autoantikörpern in patientenseren | |
DE2719836A1 (de) | Verfahren und reaktionsmittel zur konzentrationsbestimmung von thyroxin bindendem globulin | |
DE60131701T2 (de) | Immunoassay zum Nachweis von Amphetaminen und Derivaten davon | |
DE2825650C3 (de) | Verfahren zur Bestimmung des Thyroxin-bindungsindex im Serum | |
DE2530621A1 (de) | Verfahren zum bestimmen der anwesenheit von antigenen oder ihren antikoerpern in unbekannten proben | |
DE2822462A1 (de) | Verfahren zur durchfuehrung eines konkurrierenden immuntests auf freies oestriol | |
DE2847877A1 (de) | Reagenz zum nachweis der infektioesen mononucleose | |
DE69501816T3 (de) | Diagnostische Testvorrichtung zum genauen und schnellen Nachweis eines klinischen Markers zur Diagnose der Menopause |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8235 | Patent refused |